STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 104080

TO: James Spear
Location: CM1/3A01/2B01
Art Unit: 1615
September 29, 2003

Case Serial Number: 10/005511

From: P. Sheppard
Location: CM1-1E03
Phone: (703) 308-4499

sheppard@uspto.gov

Search Notes

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 09:27:55 ON 29 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 Sep 2003  VOL 139 ISS 14
FILE LAST UPDATED: 28 Sep 2003  (20030928/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=>
=>

=> d stat que l14
L3                STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE
L9          1293 SEA FILE=REGISTRY SSS FUL L3
L10               STR
```



VAR G1=X/OH/S/10/12/15/18
REP G2=(3-3) C
REP G3=(0-2) C
VAR G4=23/24/25/26/21
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
L11 85 SEA FILE=REGISTRY SUB=L9 SSS FUL L10
L12 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
L13 1 SEA FILE=REGISTRY SUB=L11 SSS FUL L12
L14 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L13

=>
=>

=> d ibib abs hitrn l14 1

L14 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1986:3120 HCAPLUS
DOCUMENT NUMBER: 104:3120
TITLE: Test strips for hematocrit-independent determination of substances in whole blood
INVENTOR(S): Pfuetzner, Ludwig; Kretzschmar, Frank; Plaschnik, Dieter; Huenniger, Henner; Kallies, Karl Heinz; Loeffler, Elisabeth; Rost, Inge; Schild, Beate; Thiele, Hans Juergen; Knabe, Guenter
PATENT ASSIGNEE(S): VEB Arzneimittelwerk Dresden, Ger. Dem. Rep.
SOURCE: Ger. (East), 10 pp.
CODEN: GEXXA8
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 222419	A1	19850515	DD 1983-255802	19831020
DD 222419	B1	19870211		

PRIORITY APPLN. INFO.: DD 1983-255802 19831020
AB A test strip for detn. of e.g. glucose in whole blood consists of a film

carrier coated with a reagent-contg. transparent polymer layer 2-15 .mu.m thick which swells rapidly in aq. media with a low absorption capacity (0.2-3.0 mg/cm2). For example, glucose was detd. in whole blood, serum, or urine with a transparent cellulose acetate film coated with a mixt. of gelatin (6 g/m2) hardened with Cr(OAc)3 (450 mg/m2), 1-(3'-sulfo-4'-phenoxy)phenyl-3-(carboxyheptadecylamido)-5-pyrazolone (369 mg/m2), 4-(N-.delta.-sulfobutyl-N-butylammonium)anilinium sulfate (240 mg/m2), glucose oxidase (10,000 units/m2), peroxidase (500 units/m2), ethylene glycol (1.5 mL/m2), and Na hexadecylsulfonate (3 mg/m2), adjusted to pH 7.4 with NaOH. After rinsing off excess sample and incubating the strip, the color developed was read visually or by transmission or reflection photometry. The results are independent of the hematocrit of whole blood, and the single-layer strip is inexpensive to manuf.

IT **99468-84-5**
RL: ANST (Analytical study)
(test strip contg., for glucose detn. in blood and urine)

=>
=>

=> fil reg
FILE 'REGISTRY' ENTERED AT 09:28:09 ON 29 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2003 HIGHEST RN 594810-89-6
DICTIONARY FILE UPDATES: 28 SEP 2003 HIGHEST RN 594810-89-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>

=>

=> d ide can l13 1

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 99468-84-5 REGISTRY
CN 1-Naphthalenesulfonic acid, 3-[(carboxyoctadecylamino)carbonyl]-4-hydroxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C30 H45 N O7 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 104:3120

=>
=>

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 09:28:26 ON 29 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 Sep 2003  VOL 139 ISS 14
FILE LAST UPDATED: 28 Sep 2003  (20030928/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=>
=>

=> d stat que l16
L3                STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE
L9          1293 SEA FILE=REGISTRY SSS FUL L3
L10               STR
```



VAR G1=X/OH/S/10/12/15/18
REP G2=(3-3) C
REP G3=(0-2) C
VAR G4=23/24/25/26/21
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
L11 85 SEA FILE=REGISTRY SUB=L9 SSS FUL L10
L12 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
L13 1 SEA FILE=REGISTRY SUB=L11 SSS FUL L12
L15 84 SEA FILE=REGISTRY ABB=ON PLU=ON L11 NOT L13
L16 20 SEA FILE=HCAPLUS ABB=ON PLU=ON L15

=>
=>

=> d ibib abs hitrn l16 1-20

L16 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:428856 HCAPLUS
DOCUMENT NUMBER: 137:20225
TITLE: Preparation of phenylmethylalkanoic acid derivatives as PPAR.alpha. agonists useful in the treatment of hyperlipidemia, arteriosclerosis, diabetes, and obesity
INVENTOR(S): Miyachi, Hiroyuki; Nomura, Masahiro; Murakami, Kouji
PATENT ASSIGNEE(S): Kyorin Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044127	A1	20020606	WO 2001-JP10355	20011128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002022552 A5 20020611 AU 2002-22552 20011128
PRIORITY APPLN. INFO.: JP 2000-363679 A 20001129
WO 2001-JP10355 W 20011128

OTHER SOURCE(S): MARPAT 137:20225
GI



I

AB The title compds. I [R1 represents trifluoromethyl, optionally substituted phenoxy, etc.; R2 represents hydrogen or lower alkoxy; R3, R4 and R5 represent each hydrogen or lower alkyl; A represents NHCO or CONH; X is located at the para-position relative to A and represents oxygen or sulfur, or X is located at the para-position relative to R2 and represents oxygen or sulfur; and n is an integer of from 0 to 2], useful as PPAR.alpha. agonists (no data) for the treatment of hyperlipidemia, arteriosclerosis, diabetes, and obesity, are prepd. For example, 2-[[4-[N-[[4-(trifluoromethyl)phenyl]methyl]carbamoyl]-3-methoxyphenyl]methyl]butyric acid was prepd.

IT **433926-32-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phenylmethylalkanoic acid derivs. as PPAR.alpha. agonists useful in treatment of hyperlipidemia and arteriosclerosis and diabetes)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:581649 HCAPLUS
DOCUMENT NUMBER: 135:163628
TITLE: Preparation of derivatives of known pesticides, with enhanced properties
INVENTOR(S): Mulvihill, Mark Joseph; Shaber, Steven Howard; Kelly, Martha Jean
PATENT ASSIGNEE(S): Rohm and Haas Company, USA
SOURCE: PCT Int. Appl., 1646 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056358	A2	20010809	WO 2001-US651	20010126

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6376548	B1	20020423	US 2000-493865	20000128
AU 2001030875	A5	20010814	AU 2001-30875	20010126
WO 2002072559	A1	20020919	WO 2002-US7423	20020312

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	US 2000-178878P	P	20000128
	US 2000-493865	A	20000128
	WO 2001-US651	W	20010126
	US 2001-804704	A	20010313

OTHER SOURCE(S): MARPAT 135:163628

AB A very large no. of derivs. of known pesticides were prepd. The moieties substituted to the known pesticides enhance or favorably modify the activity and properties of the parent pesticide.

IT **353757-98-9P 353757-99-0P**
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. as pesticide with enhanced properties)

L16 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	1998:527379 HCAPLUS
DOCUMENT NUMBER:	129:176908
TITLE:	Soluble chromophores having improved solubilizing groups and their use
INVENTOR(S):	Hall-Goulle, Veronique; Bize, Aline
PATENT ASSIGNEE(S):	Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE:	PCT Int. Appl., 64 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9832802	A1	19980730	WO 1998-EP248	19980117

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG

AU 9862109	A1	19980818	AU 1998-62109	19980117
EP 968250	A1	20000105	EP 1998-904092	19980117
EP 968250	B1	20010418		

R: CH, DE, FR, GB, IT, LI

JP 2001513119	T2	20010828	JP 1998-531549		19980117
TW 444051	B	20010701	TW 1998-87100901		19980123
US 6274728	B1	20010814	US 1999-465868		19991216
PRIORITY APPLN. INFO.:			CH 1997-171	A	19970127
			WO 1998-EP248	W	19980117
			US 1998-13659	B1	19980226

OTHER SOURCE(S): MARPAT 129:176908

AB The colorants A(B)x (x = 1-8; A = radical of a chromophore of the quinacridone, anthraquinone, perylene, indigo, quinophthalone, indanthrone, isoindolinone, isoindoline, dioxazine, azo, phthalocyanine or diketopyrrolopyrrole series; B = H or solubilizing group) are obtained whereby A is bonded to x groups B via one or more hetero atoms, those hetero atoms being selected from the group consisting of N, O, and S and forming part of the radical A. The colorants are used in high-mol.-wt. org. materials, thermo-, photo-, or chemo-sensitive recording materials, light-sensitive neg. or pos. resist compns., ink compns. for ink-jet printing, and color tapes for thermal transfer printing. The sol. chromophore derivs. can be converted to the underivatized form (B = H) by heating after they are incorporated into a substrate. Thus, bis(1,1-dimethyl-3,7-dioxa-1-heptyl) oxydicarbonate was prepd. and used to treat C.I. Pigment Violet 37, giving the red tetrakis(1,1,-dimethyl-3,7-dioxa-1-heptyloxycarbonyl) deriv. of C.I. Pigment Violet 37 in 65% yield; this pigment was used in a coating compn.

IT **211322-06-4P 211322-07-5P**
RL: IMF (Industrial manufacture); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(pigment; prepn. of pigments contg. labile solubilizing groups)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:618073 HCAPLUS
DOCUMENT NUMBER: 127:262561
TITLE: synthesis and DNA alkylating activity of MCBI analogs of CC-1065 and the duocarmycins
INVENTOR(S): Boger, Dale L.
PATENT ASSIGNEE(S): Scripps Research Institute, USA; Boger, Dale L.
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732850	A1	19970912	WO 1997-US3641	19970307
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2246783	AA	19970912	CA 1997-2246783	19970307
AU 9719902	A1	19970922	AU 1997-19902	19970307
AU 711974	B2	19991028		
EP 888301	A1	19990107	EP 1997-908059	19970307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000506168	T2	20000523	JP 1997-531987	19970307
US 5985908	A	19991116	US 1998-142337	19980904

PRIORITY APPLN. INFO.: US 1996-13024P P 19960308
WO 1997-US3641 W 19970307
OTHER SOURCE(S): MARPAT 127:262561
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB MCBI (7-methoxy-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one) (I) (R1 = H) is employable as a DNA alkylating agent and can be incorporated into analogs of CC-1065 and the duocarmycins I (R1 = Q1, Q2, Q3, Q4) for constructing regioselective DNA alkylating agents. Thus, I (R1 = Q1) (II) is prepd. by reacting 1-(chloromethyl)-5-hydroxy-8-methoxy-1,2-dihydro-3H-benz[e]indole with Q1-CO2H followed by cyclopropanation with NaH in THF-DMF. The relative rates of DNA alkylation do not follow the relative rates of acid-catalyzed solvolysis.

IT **196306-02-2P 196306-03-3P 196306-04-4P**
196306-10-2P 196306-21-5P 196306-22-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and DNA alkylating activity of MCBI analogs of CC-1065 and the duocarmycins)

L16 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:549377 HCAPLUS
DOCUMENT NUMBER: 127:161997
TITLE: Carbamoyloxy derivatives of mutilin and their use as antibacterials
INVENTOR(S): Hinks, Jeremy David; Takle, Andrew Kenneth; Hunt, Eric
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK; Hinks, Jeremy David; Takle, Andrew Kenneth; Hunt, Eric
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9725309	A1	19970717	WO 1996-EP5874	19961219
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2240467	AA	19970717	CA 1996-2240467	19961219
AU 9713078	A1	19970801	AU 1997-13078	19961219
AU 715229	B2	20000120		
EP 874809	A1	19981104	EP 1996-944684	19961219
EP 874809	B1	20030827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
CN 1214039	A	19990414	CN 1996-180177	19961219
BR 9612426	A	19990713	BR 1996-12426	19961219
JP 2000503642	T2	20000328	JP 1997-524826	19961219
ZA 9700017	A	19980702	ZA 1997-17	19970102
AP 872	A	20000928	AP 1997-1047	19970721

	W: BW, GM, GH, KE, LS, MW, SD, SZ, UG, ZM, ZW						
WO	9805659	A1	19980212	WO	1997-EP4166	19970729	
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM						
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG						
AU	9742036	A1	19980225	AU	1997-42036	19970729	
EP	934316	A1	19990811	EP	1997-940050	19970729	
EP	934316	B1	20021016				
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI						
BR	9711008	A	19990817	BR	1997-11008	19970729	
CN	1231665	A	19991013	CN	1997-198347	19970729	
NZ	333926	A	20000526	NZ	1997-333926	19970729	
JP	2000515532	T2	20001121	JP	1998-507584	19970729	
AT	226203	E	20021115	AT	1997-940050	19970729	
ES	2182114	T3	20030301	ES	1997-940050	19970729	
ZA	9706817	A	19990201	ZA	1997-6817	19970731	
NO	9803074	A	19980831	NO	1998-3074	19980702	
US	6020368	A	20000201	US	1998-101210	19981204	
NO	9900463	A	19990201	NO	1999-463	19990201	
KR	2000029748	A	20000525	KR	1999-700856	19990201	
US	6239175	B1	20010529	US	1999-467695	19991221	
PRIORITY APPLN. INFO.:				GB	1996-48	A	19960103
				GB	1996-16305	A	19960802
				WO	1996-EP5874	W	19961219
				GB	1997-12963	A	19970619
				WO	1997-EP4166	W	19970729
				US	1998-101210	A3	19981204

OTHER SOURCE(S): MARPAT 127:161997

GI



I



II

AB Derivs. of mutilin of formula [I; Y = (un)substituted carbamoyloxy; R1 = vinyl, Et] and their pharmaceutically acceptable salts, useful in the treatment of bacterial infections (no data), are prepd. Thus, (3R)-epimutilin deriv. II (R = H) was treated with Ph isocyanate in CH2Cl2 contg. N,N-diisopropylethylamine at room temp. for 7 days to give II (R = PhNHCO), which in dioxane was treated with a satd. soln. of ZnCl2 in concd. HCl to give the title compd. mutilin 14-phenylcarbamate.

IT **193535-05-6P 193536-54-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of carbamoyloxymutilins as antibacterials)

IT **193535-03-4P 193535-31-8P 193535-81-8P**
193535-83-0P 193536-65-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of carbamoyloxymutilins as antibacterials)

IT **193537-50-7P 193537-96-1P 193538-05-5P**
193538-06-6P 193538-07-7P 193538-09-9P
193538-63-5P 193538-65-7P 193538-66-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of carbamoyloxymutilins as antibacterials)

L16 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:405468 HCAPLUS
DOCUMENT NUMBER: 127:42170
TITLE: Silver halide color photographic material containing development-inhibitor-releasing agent
INVENTOR(S): Sato, Naoki; Ishige, Osamu
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09114055	A2	19970502	JP 1995-270197	19951018

PRIORITY APPLN. INFO.: JP 1995-270197 19951018
GI



I

AB The title material contains a compd. SA(time)nZJX (S = C.ltoreq.10 substituent; A = group releasing (time)nZX upon reaction with oxidized developing agents; time = timing group; Z = N-contg. heterocycle; J = OCO bond-contg. group; X = substituent; n = 0-2). The variation in processing of the material due to the accumulation of released inhibitor in the processing soln. is less, and high quality color image are obtained. Thus, a multilayer color photog. film was prepd. by using I for the compd.

IT **190581-14-7**
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(photog. development inhibitor releasing coupler giving clear images)

L16 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1993:505802 HCAPLUS
DOCUMENT NUMBER: 119:105802
TITLE: Electrophotographic photoreceptors using azo type charge-generating agent
INVENTOR(S): Karasawa, Akio; Ito, Naoto; Oguchi, Takahisa
PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04229868	A2	19920819	JP 1990-414695	19901227
JP 2788127	B2	19980820		

PRIORITY APPLN. INFO.: JP 1990-414695 19901227
OTHER SOURCE(S): MARPAT 119:105802
GI



I

AB The photoreceptors comprise a photosensitive layer contg. .gtoreq.1 azo compd. I [R = (substituted) alkyl, arom. hydrocarbon ring or heterocyclic ring; Z = (substituted) arom. hydrocarbon ring or heterocyclic ring which may bond through a binding group; n = 2-4]. The photoreceptors show high photosensitivity and good durability in repeated use.

IT **146173-09-3 146173-10-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(diazo coupling of)

IT **146173-13-9 146173-14-0 146173-15-1 146173-16-2 146173-17-3 146173-18-4 146173-19-5 146173-20-8 146173-21-9 146173-22-0 146173-23-1 146173-24-2 146173-25-3**
RL: TEM (Technical or engineered material use); USES (Uses)
(electrophotog. photoreceptor charge-generating agent)

IT **146173-11-7P 146173-12-8P**
RL: PREP (Preparation)
(prepn. of, electrophotog. photoreceptor charge-generating agent)

L16 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:473091 HCAPLUS
DOCUMENT NUMBER: 119:73091
TITLE: Synthesis and antifungal activities of pradimicin A derivatives modification of the alanine moiety
AUTHOR(S): Nishio, Maki; Ohkuma, Hiroaki; Kakushima, Masatoshi; Ohta, Shinichi; Iimura, Seiji; Hirano, Minoru; Konishi, Masataka; Oki, Toshikazu
CORPORATE SOURCE: Bristol-Myers Squibb Res. Inst., Tokyo, 153, Japan
SOURCE: Journal of Antibiotics (1993), 46(3), 494-9

CODEN: JANTAJ; ISSN: 0021-8820
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Title pradimicin A derivs. I (R = OMe, OEt, OCH2O2CMe3, NH2, NHMe, NHEt, D-Ala-OH, L-Ala-OH, L-Asp-OH, L-Lys-OH, Gly-OH) were prepd. and in vitro and in vivo antifungal activities of the derivs. were examd. in comparison with those of pradimicin A (I, R = OH). The amide derivs. showed activities comparable to pradimicin A, indicating that the free carboxyl group can be modified without impairing the antifungal activity.

IT **148676-95-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, with dimethylamine)

IT **148676-96-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrogenolysis of)

L16 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1991:559494 HCAPLUS
DOCUMENT NUMBER: 115:159494
TITLE: A short efficient route to acronycine and other acridones
AUTHOR(S): Horne, Stephen; Rodrigo, Russell
CORPORATE SOURCE: Guelph-Waterloo Cent. Grad. Work Chem., Univ. Waterloo, Waterloo, ON, N2L 3G1, Can.
SOURCE: Journal of the Chemical Society, Chemical Communications (1991), (15), 1046-8
CODEN: JCCCAT; ISSN: 0022-4936
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 115:159494
GI



I

AB A Fries type of rearrangement of N-tosyl-o-iodobenzanilides, triggered by lithium-iodine exchange at low temp. is the key step in a general, regiospecific synthesis of acridones, e.g. I.

IT **136138-31-3P 136138-32-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and Fries rearrangement of)

L16 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1991:491783 HCAPLUS
DOCUMENT NUMBER: 115:91783
TITLE: Syntheses of tolrestat analogs containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives
AUTHOR(S): Wrobel, Jay; Millen, Jane; Sredy, Janet; Dietrich, Arlene; Gorham, Beverly J.; Malamas, Michael; Kelly, Joseph M.; Bauman, John G.; Harrison, Maria C.; et al.
CORPORATE SOURCE: Wyeth-Ayerst Res., Inc., Princeton, NJ, 08543-8000, USA
SOURCE: Journal of Medicinal Chemistry (1991), 34(8), 2504-20
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of aldose reductase inhibitors were prepd. which were analogs of the potent, orally active inhibitor tolrestat I (R = H; R1 = Me; R2 = CF3; R3 = OH; X = S). These compds., e.g., I (R = 2-F, Cl, Me, OMe, OEt, OPh, OCH2Ph, 3-F, Br, Me, Ph, 7-Me; R1 = Me, CO2Me, CO2Et; R2 = CF3, Br; R3 = OH, NH2, NHCO2Et; X = S, O) have an extra substituent on one of the unoccupied positions on the naphthalene ring. These compds. were evaluated in two in vitro systems:an isolated enzyme prepn. from bovine lens to assess their intrinsic inhibitory activity and an isolated sciatic nerve assay to det. their ability to penetrate membranes of nerve tissue. These compds. were also evaluated in vivo as inhibitors of galactitol accumulation in the lens, sciatic nerve, and diaphragm of galactose-fed rats. In general, compds. I were potent inhibitors of bovine lens aldose reductase. I (R = 2-halo) exhibited high activity in the nerve of the 4-day-galactose-fed rat, and in several instances, the primary amide

prodrug I (R1 = Me; R2 = CF2; R3 = NH2; X = O) enhanced the in vivo potency of the resp. carboxylic acid I (R3 = OH). Two 2-fluoro-derivs. I (R = 2-F, R1 = Me, CO2Me; R2 = CF3; R3 = NH2, OH; X = O), had esp. high activity in vivo and were chosen for addnl. studies. These compds. were found to be approx. equipotent to tolrestat in the sciatic nerve of the galactose-fed rat and the STZ rat, as judged by their ED50's in these assays. Although primary amide analog I (R = 2-F; R1 = Me; R2 = CF3; R3 = NH2; X = O) did not have intrinsic inhibitory activity toward aldose reductase, it was metabolized to an active form in vivo and also in vitro within the sciatic nerve.

IT **122670-49-9P 122670-50-2P 122670-51-3P**
122670-52-4P 122670-53-5P 122670-56-8P
122670-87-5P 134057-80-0P 134058-04-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and aldose reductase inhibition by)

IT **122670-73-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrolysis of)

IT **122670-77-3P 134058-02-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with tert-Bu bromoacetate)

IT **122670-57-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and selective hydrolysis of)

IT **122670-72-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with tert-Bu bromoacetate)

L16 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1991:81247 HCAPLUS
DOCUMENT NUMBER: 114:81247
TITLE: Preparation of benzoylaminooxyacetic acid esters as herbicides
INVENTOR(S): Grina, Jonas; Ebner, Cuno; Kirkpatrick, Joel Lee; Steiger, Arthur; Busteed, Roslynn
PATENT ASSIGNEE(S): Sandoz A.-G., Switz.; Sandoz-Patent-G.m.b.H.; Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 381913	A1	19900816	EP 1989-810934	19891211
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
HU 53603	A2	19901128	HU 1989-6342	19891201
CA 2005256	AA	19900614	CA 1989-2005256	19891212
DK 8906270	A	19900615	DK 1989-6270	19891212
AU 8946161	A1	19900621	AU 1989-46161	19891212
CN 1043496	A	19900704	CN 1989-109417	19891213
JP 02212464	A2	19900823	JP 1989-323656	19891213
BR 8906452	A	19900828	BR 1989-6452	19891214
ZA 8909582	A	19910828	ZA 1989-9582	19891214

PRIORITY APPLN. INFO.: GB 1988-29204 19881214
OTHER SOURCE(S): MARPAT 114:81247
GI



I



II



III

AB The title compds. I and II [X = CO, SO2; Y = O, S; R1 = H, (substituted) alkyl, alkenyl, alkynyl, etc.; R2 = H, alkyl, alkenyl, alkoxy, phenoxy, etc.] were prepd. Reaction of benzoylaminooxyacetate III with AcCl in the presence of pyridine gave I (X = CO; R1 = R2 = Me; Y = O). I (X = CO; Y = O; R1 = Me; R2 = cyclopropyl) at 0.25 kg/ha (pre- or postemergent) gave substantial control of weeds (Setaria viridis, Solanum nigrum, etc.). Formulations contg. I are given.

IT **131777-37-2P 131777-58-7P 131777-67-8P**
131777-71-4P 131777-72-5P 131777-77-0P
131797-25-6P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as herbicide)

L16 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1989:534749 HCAPLUS
DOCUMENT NUMBER: 111:134749
TITLE: N-(alkoxycarbonyl)-N-naphthoylglycines as aldose reductase inhibitors and pharmaceutical compositions containing them
INVENTOR(S): Wrobel, Jay E.; Sestanj, Kazimir
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: U.S., 18 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4820727	A	19890411	US 1987-137406	19871223
CA 1326680	A1	19940201	CA 1988-586305	19881219
WO 8905793	A1	19890629	WO 1988-US4625	19881221
W: JP				
JP 02502727	T2	19900830	JP 1989-500653	19881221
EP 322256	A1	19890628	EP 1988-312314	19881223
EP 322256	B1	19930324		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 87301	E	19930415	AT 1988-312314	19881223

PRIORITY APPLN. INFO.: US 1987-137406 19871223
WO 1988-US4625 19881221

EP 1988-312314 19881223

OTHER SOURCE(S): CASREACT 111:134749; MARPAT 111:134749

GI



I



II

AB The title compds. [I: R1 = halo, C1-3 perfluoroalkoxy; R2 = alkyl; X = OH, NH2, alkoxy] and their pharmaceutically acceptable salts, useful as aldose reductase inhibitors, are prepd. Naphthoic acid II (R3 = OH) (prepn. given) was reacted with H2NCH2CO2CMe3 to give II (R3 = NHCH2CO2CMe3), which was treated with ClCO2Me to give I (R1 = F, R2 = Me, X = CMe3), which was hydrolyzed to give I (R1 = F, R2 = Me, X = OH)) (III). III in an in vivo study using galactosemic rats showed 86% inhibition of aldose reductase at 10-7 M vs. 65% for tolrestat at the same concn.

IT **122670-57-9P 122670-72-8P 122670-73-9P**
122670-75-1P 122670-77-3P 122670-78-4P
122670-83-1P 122670-84-2P 122670-85-3P
122670-86-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of aldose reductase inhibitor)

IT **122670-49-9P 122670-50-2P 122670-51-3P**
122670-52-4P 122670-53-5P 122670-56-8P
122670-87-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of as aldose reductase inhibitor)

L16 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1982:406594 HCAPLUS
DOCUMENT NUMBER: 97:6594
TITLE: The use of isoquinolinetriones in the synthesis of benzo[c]phenanthridine alkaloids
AUTHOR(S): Pollers-Wieers, C.; Vekemans, J.; Toppet, S.; Hoornaert, G.
CORPORATE SOURCE: Dep. Chem., Katholieke Univ. Leuven, Louvain, 3030, Belg.
SOURCE: Tetrahedron (1981), 37(24), 4321-6
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III



IV

AB Wittig-Horner reaction of isoquinolinetriones I (R = H, OMe, NO2) with (EtO)2P(O)CH(CO2Et)CH2C6H3R12-3,4 (R1 = H; R12 = OCH2O) gave II (R = H, OMe, NO2, R12 = OCH2O; R = OMe, R1 = H) which on enolization and methylation with CH2N2 followed by intramol. photochem. cyclocondensation gave the benzophenanthridines III (R, R1 as before). In the latter cyclization III (R = OMe, R1 = H) was only a minor product (<5%), the major product being IV, which was obtained in 54% yield.

IT **82083-60-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L16 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1977:131050 HCAPLUS
DOCUMENT NUMBER: 86:131050
TITLE: Diffusion-transfer color photographic film unit
INVENTOR(S): Yoshida, Yoshinobu; Ohishi, Yasushi
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 32 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 51027934	A2	19760309	JP 1974-101681	19740903

PRIORITY APPLN. INFO.: JP 1974-101681 19740903

AB In prepg. a color diffusion-transfer photog. film unit obtained by depositing on a transparent support a neg. Ag halide emulsion layer contg. a diffusion-resistant coupler which forms a nondiffusible dye on reacting with the oxidized form of an arom. primary amine color developer, and a nonphotosensitive hydrophilic colloid layer contg. a diffusion-resistant coupler which upon development yields a diffusible pos. dye image by reaction with the oxidized form of the arom. primary amine color developer, a 3rd coupler is used which forms a dye absorbing in a region necessary to compensate for the undesirable absorption of the dye formed by the coupler in the Ag halide emulsion layer.

IT **62050-96-8**
RL: TEM (Technical or engineered material use); USES (Uses)
(photog. coupler, for color diffusion-transfer photog. films)

L16 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1975:514023 HCAPLUS
DOCUMENT NUMBER: 83:114023
TITLE: Substituted benzene derivatives
INVENTOR(S): Richter, Sidney B.; Barnas, Eugene
PATENT ASSIGNEE(S): Velsicol Chemical Corp., USA
SOURCE: U.S., 7 pp. Division of U.S. 3,840,874.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3891701	A	19750624	US 1972-299497	19721020
US 3649664	A	19720314	US 1968-765962	19681008
US 3804874	A	19740416	US 1971-148197	19710528

PRIORITY APPLN. INFO.: US 1968-765962 19681008
US 1971-148197 19710526

GI For diagram(s), see printed CA Issue.
AB The amides I (R = OMe; R1 = Ac, Me2CHO2C, EtCO, PhCO, EtO2C p-toluoyl), which are useful as acaricides, were prepd. by reaction of 3,2,6-Cl(MeO)2C6H2COCl with MeONH2.HCl to give I (R = H, R1 = OMe), which reacted with, e.g., Ac2O, Me2CHO2CCl, EtCOCl, PhCOCl, EtO2CCl, or p-MeC6H4COCl; in some cases II were also obtained. II (R1 = Me2CHO2C) was also an effective acaricide.
IT **36335-52-1P 36405-56-8P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and acaricidal activity of)

L16 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1974:569329 HCAPLUS
DOCUMENT NUMBER: 81:169329
TITLE: O-Alkyl-.alpha.-alkanoyloxybenzaldoximes
INVENTOR(S): Richter, Sidney, M.; Barnas, Eugene F.
PATENT ASSIGNEE(S): Velsicol Chemical Corp.
SOURCE: U.S., 4 pp. Division of U.S. 3,597,467 (CA 75;110065f).
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3839439	A	19741001	US 1970-82195	19701019
US 3597467	A	19710803	US 1968-779247	19681126

PRIORITY APPLN. INFO.: US 1968-779247 19681126
GI For diagram(s), see printed CA Issue.
AB The benzamides I and the benzaldoximes II (R, R1 = Et, Me; R2 = EtS, EtO, Me2CHO, Me, Pr, PrO), useful as acaricides, were prepd. E.g., reaction of MeONH2.HCl with 6,3,2-Cl2(MeO)C6H2COCl gave 6,3,2-Cl2(MeO)C6H2CONHO Me, which reacted with ClC(O)SEt to give a mixt. of I and II (R = R1 = Me, R2 = EtS). Six I and three II were prepd. I (R = R1 = Me, R2 = EtS) at 1000-3500 ppm killed 89-94% of the mites.
IT **33605-85-5P 33605-86-6P 33605-88-8P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic

preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and acaricidal activity of)

L16 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1974:403621 HCAPLUS
DOCUMENT NUMBER: 81:3621
TITLE: O-Acylated benzohydroxamates
INVENTOR(S): Richter, Sidney B.; Barnas, Eugene F.
PATENT ASSIGNEE(S): Velsicol Chemical Corp.
SOURCE: U.S., 6 pp. Division of U.S. 3,649,664 (CA 76;153374u).
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3804874	A	19740416	US 1971-148197	19710528
US 3649664	A	19720314	US 1968-765962	19681008
US 3891701	A	19750624	US 1972-299497	19721020

PRIORITY APPLN. INFO.: US 1968-765962 19681008
US 1971-148197 19710526

GI For diagram(s), see printed CA Issue.
AB Division of U.S. 3,649,664 (CA 76: 153374u). Benzamides (I; R = Ac, Me2CHO2C, EtCO, Bz, EtO2C, p-toluoyl) and their isomers (II) were prepd. by reaction of 3,2,6-Cl(MeO)2C6H2CONHOMe with RCl. I (R = Ac) at 100 ppm gave 89% mortality of Tetranychus urticae after 5 days. Other I and II were also useful as acaricides.
IT **36335-52-1P 36405-56-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L16 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1973:439343 HCAPLUS
DOCUMENT NUMBER: 79:39343
TITLE: Control of acarids using 3-halobenzamides
INVENTOR(S): Richter, Sidney B.; Barnas, Eugene F.
PATENT ASSIGNEE(S): Velsicol Chemical Corp.
SOURCE: U.S., 6 pp. Division of U.S. 3,649,664 (CA 76;153374u).
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3733414	A	19730515	US 1971-148198	19710528
US 3649664	A	19720314	US 1968-765962	19681008

PRIORITY APPLN. INFO.: US 1968-765962 19681008
AB 3-Halobenzamides (I) and the isomeric imidoanhydrides (II), where X = halogen, R1 and R3 = alkyl, R2 = alkyl or alkoxy, and R4 = alkyl, alkenyl, alkoxy, alkylthio, or III (where A = O, S, or alkylene and Z = alkyl, alkenyl, alkoxy, alkylthio, halogen, nitro, cyano, or dialkylamino), possessed acaricidal properties. Thus, N-acetyl-3-chloro-N,2,6-trimethoxybenzamide [36335-49-6] (I, where X = Cl, R1 = R3 = R4 = Me, and R2 = OMe) was prepd. and killed 89% of the two-spotted spider mites (Tetranychus urticae) infesting bush lima bean plants when the plants were watered with a soln. contg. 100 ppm of the benzamide deriv., and O-methyl-.alpha.-[(isopropoxycarbonyl)oxy]-2,6-dimethoxy-3-

chlorobenzaldoxime [36335-50-9] (II, where X = Cl, R1 = R3 = Me, R2 = OMe, and R4 = OCH2Me2) killed 100% of the mites at 80 ppm.

IT **36335-52-1 36405-56-8**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(acaricides)

L16 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1972:153374 HCAPLUS
DOCUMENT NUMBER: 76:153374
TITLE: Acaricidal N-acylated benzohydroxamates
INVENTOR(S): Richter, Sidney B.; Barnas, Eugene F.
PATENT ASSIGNEE(S): Velsicol Chemical Corp.
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3649664	A	19720314	US 1968-765962	19681008
US 3733414	A	19730515	US 1971-148198	19710528
US 3804874	A	19740416	US 1971-148197	19710528
US 3891701	A	19750624	US 1972-299497	19721020

PRIORITY APPLN. INFO.: US 1968-765962 19681008
US 1971-148197 19710526

GI For diagram(s), see printed CA Issue.

AB The title compds. (I and II) were prepd. and tested on Tetranychus urticae [Tetranychus telarius]. Thus, 3,2,6-Cl(MeO)2C6H2CONHOMe was refluxed 18 hr with Me2CHO2CCl in C6H6-C5H5N and sepd. chromatog. into I and II (R = OCHMe2). Similarly prepd. were I (R = Me, Et, Ph, p-tolyl, OEt) and II (R = Ph, p-tolyl). I (R = Me) gave 89% mortality of T. telarius on lima bean plants after 5 days at 100 ppm.

IT **36335-52-1P 36405-56-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L16 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1971:510065 HCAPLUS
DOCUMENT NUMBER: 75:110065
TITLE: Acaricidal N,2-dimethoxy-N-(substituted carbonyl)-3,6-dichlorobenzamides
INVENTOR(S): Richter, Sidney B.; Barnas, Eugene F.
PATENT ASSIGNEE(S): Velsicol Chemical Corp.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3597467	A	19710803	US 1968-779247	19681126
US 3839439	A	19741001	US 1970-82195	19701019
US 3891687	A	19750624	US 1970-82181	19701019

PRIORITY APPLN. INFO.: US 1968-779247 19681126

GI For diagram(s), see printed CA Issue.

AB The title compds. (I) and their isomers (II) are prepd. from an N-alkoxybenzamide. Thus, MeONH2.HCl and NaOH in 1.2 H2O-CHCl3 stirred

(cooling bath) with addn. of 2,3,6-MeO(Cl2)C6H2COCl and the mixt. stirred several hr gave 2,3,6-MeO(Cl2)C6H2CONHOMe (III). III, ClCOSEt and C5H5N refluxed 5 hr in C6H6 yielded a mixt. of I and II (R1 = R2 = Me, R3 = EtS, X1 = X2 = Cl), m. 71-4.degree.. Similarly were prepd. isomeric mixts. of I and II (R1 = R2 = Me, R3 = EtO, X1 = X2 = Cl; R1 = R2 = Me, R3 = Me2CHO, X1 = X2 = Cl). I (II) control various species of mites and ticks.

IT **33605-85-5P 33605-86-6P 33605-88-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

=> fil caold
FILE 'CAOLD' ENTERED AT 09:29:23 ON 29 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>
=>

=> d stat que l17 nos
L3 STR
L9 1293 SEA FILE=REGISTRY SSS FUL L3
L10 STR
L11 85 SEA FILE=REGISTRY SUB=L9 SSS FUL L10
L17 1 SEA FILE=CAOLD ABB=ON PLU=ON L11

=>
=>

=> d all l17 1

L17 ANSWER 1 OF 1 CAOLD COPYRIGHT 2003 ACS on STN
AN CA50:11279i CAOLD
TI synthesis of 3 - fluoro - 4 - hydroxyphenylacetic acid
AU Lock, G.
IT **314-66-9** 345-72-2 350-29-8 351-52-0 351-54-2
370-60-5 403-20-3 404-46-6 404-90-0 452-14-2 455-72-1
458-09-3 574-74-3

=>
=>

=> fil reg
FILE 'REGISTRY' ENTERED AT 09:29:45 ON 29 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2003 HIGHEST RN 594810-89-6
DICTIONARY FILE UPDATES: 28 SEP 2003 HIGHEST RN 594810-89-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
=>

=> d reg l11 tot

1	RN	433926-32-0	REGISTRY
2	RN	353757-99-0	REGISTRY
3	RN	353757-98-9	REGISTRY
4	RN	211322-07-5	REGISTRY
5	RN	211322-06-4	REGISTRY
6	RN	196306-22-6	REGISTRY
7	RN	196306-21-5	REGISTRY
8	RN	196306-10-2	REGISTRY
9	RN	196306-04-4	REGISTRY
10	RN	196306-03-3	REGISTRY
11	RN	196306-02-2	REGISTRY
12	RN	193538-66-8	REGISTRY
13	RN	193538-65-7	REGISTRY
14	RN	193538-63-5	REGISTRY
15	RN	193538-09-9	REGISTRY
16	RN	193538-07-7	REGISTRY
17	RN	193538-06-6	REGISTRY
18	RN	193538-05-5	REGISTRY
19	RN	193537-96-1	REGISTRY
20	RN	193537-50-7	REGISTRY
21	RN	193536-65-1	REGISTRY
22	RN	193536-54-8	REGISTRY
23	RN	193535-83-0	REGISTRY
24	RN	193535-81-8	REGISTRY
25	RN	193535-31-8	REGISTRY
26	RN	193535-05-6	REGISTRY
27	RN	193535-03-4	REGISTRY
28	RN	190581-14-7	REGISTRY
29	RN	148676-96-4	REGISTRY
30	RN	148676-95-3	REGISTRY
31	RN	146173-25-3	REGISTRY
32	RN	146173-24-2	REGISTRY
33	RN	146173-23-1	REGISTRY
34	RN	146173-22-0	REGISTRY
35	RN	146173-21-9	REGISTRY
36	RN	146173-20-8	REGISTRY
37	RN	146173-19-5	REGISTRY
38	RN	146173-18-4	REGISTRY
39	RN	146173-17-3	REGISTRY

```
40          RN              146173-16-2  REGISTRY
41          RN              146173-15-1  REGISTRY
42          RN              146173-14-0  REGISTRY
43          RN              146173-13-9  REGISTRY
44          RN              146173-12-8  REGISTRY
45          RN              146173-11-7  REGISTRY
46          RN              146173-10-6  REGISTRY
47          RN              146173-09-3  REGISTRY
48          RN              136138-32-4  REGISTRY
49          RN              136138-31-3  REGISTRY
50          RN              134058-04-1  REGISTRY
51          RN              134058-02-9  REGISTRY
52          RN              134057-80-0  REGISTRY
53          RN              131797-25-6  REGISTRY
54          RN              131777-77-0  REGISTRY
55          RN              131777-72-5  REGISTRY
56          RN              131777-71-4  REGISTRY
57          RN              131777-67-8  REGISTRY
58          RN              131777-58-7  REGISTRY
59          RN              131777-37-2  REGISTRY
60          RN              122670-87-5  REGISTRY
61          RN              122670-86-4  REGISTRY
62          RN              122670-85-3  REGISTRY
63          RN              122670-84-2  REGISTRY
64          RN              122670-83-1  REGISTRY
65          RN              122670-78-4  REGISTRY
66          RN              122670-77-3  REGISTRY
67          RN              122670-75-1  REGISTRY
68          RN              122670-73-9  REGISTRY
69          RN              122670-72-8  REGISTRY
70          RN              122670-57-9  REGISTRY
71          RN              122670-56-8  REGISTRY
72          RN              122670-53-5  REGISTRY
73          RN              122670-52-4  REGISTRY
74          RN              122670-51-3  REGISTRY
75          RN              122670-50-2  REGISTRY
76          RN              122670-49-9  REGISTRY
77          RN               99468-84-5  REGISTRY
78          RN               82083-60-1  REGISTRY
79          RN               62050-96-8  REGISTRY
80          RN               36405-56-8  REGISTRY
81          RN               36335-52-1  REGISTRY
82          RN               33605-88-8  REGISTRY
83          RN               33605-86-6  REGISTRY
84          RN               33605-85-5  REGISTRY
85          RN                 314-66-9  REGISTRY


=>
=>
=> d ide can l11 1 2 4 6 12 19 21 22 23 28 29 31 48 50 52 53 54 60 77 78 79 80 81 82 85

L11  ANSWER 1 OF 85  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   433926-32-0  REGISTRY
CN   Carbamic acid, (4-hydroxy-2-methoxybenzoyl)-, 1,1-dimethylethyl ester
     (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C13 H17 N O5
SR   CA
LC   STN Files:   CA, CAPLUS
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20225

L11 ANSWER 2 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 353757-99-0 REGISTRY
CN Hydrazinecarboxylic acid, 2-(3,5-dimethylbenzoyl)-2-(1,1-dimethylethyl)-1-(2-ethyl-3-methoxybenzoyl)-, 1-(acetyloxy)ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C28 H36 N2 O7
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:163628

L11 ANSWER 4 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 211322-07-5 REGISTRY
CN Carbamic acid, [(3,3'-dimethoxy[1,1'-biphenyl]-4,4'-diyl)bis[azo(2-hydroxy-1,3-naphthalenediyl)carbonyl]]bis[(2-methoxyphenyl)-, bis[2-(2-methoxyethoxy)-1,1-dimethylethyl] ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C66 H68 N6 O16
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 129:176908

L11 ANSWER 6 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 196306-22-6 REGISTRY
CN Carbamic acid, [[1-iodo-7-methoxy-4-(phenylmethoxy)-2-naphthalenyl]carbonyl]-2-propenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H28 I N O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:262561

L11 ANSWER 12 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 193538-66-8 REGISTRY
CN Carbamic acid, [3-[2-(dimethylamino)ethoxy]-4-fluorobenzoyl]-, 6-ethenyldecahydro-1-methoxy-4,6,9,10-tetramethyl-5-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester, [1R-(1.alpha.,3a.alpha.,4.beta.,6.alpha.,8.beta.,9.alpha.,9a.alpha.,10R*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H47 F N2 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:161997

L11 ANSWER 19 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 193537-96-1 REGISTRY
CN Carbamic acid, (3-hydroxybenzoyl)-, 6-ethenyldecahydro-1-methoxy-4,6,9,10-tetramethyl-5-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester, [1R-(1.alpha.,3a.alpha.,4.beta.,6.alpha.,8.beta.,9.alpha.,9a.alpha.,10R*)]-

(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H39 N O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:161997

L11 ANSWER 21 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 193536-65-1 REGISTRY
CN Carbamic acid, [3-[2-(dimethylamino)ethoxy]-4-fluorobenzoyl]-, 6-ethyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester, [3aS-(3a.alpha.,4.beta.,5.alpha.,6.alpha.,8.beta.,9.alpha.,9a.beta.,10S*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H47 F N2 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:161997

L11 ANSWER 22 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 193536-54-8 REGISTRY
CN Carbamic acid, [3-[2-(dimethylamino)ethoxy]-4-fluorobenzoyl]-, 6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester, [3aS-(3a.alpha.,4.beta.,5.alpha.,6.alpha.,8.beta.,9.alpha.,9a.beta.,10S*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H45 F N2 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:161997

L11 ANSWER 23 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 193535-83-0 REGISTRY
CN Carbamic acid, [4-[2-(dimethylamino)ethoxy]-3-fluorobenzoyl]-, 6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester, [3aS-(3a.alpha.,4.beta.,5.alpha.,6.alpha.,8.beta.,9.alpha.,9a.beta.,10S*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H45 F N2 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:161997

L11 ANSWER 28 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 190581-14-7 REGISTRY
CN Carbamic acid, [[4-[4-[[[1-[2-(benzoyloxy)-1-hydroxyethyl]-1H-tetrazol-5-yl]thio]methyl]-2-nitrophenoxy]-1-hydroxy-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C30 H24 N6 O10 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:42170

L11 ANSWER 29 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 148676-96-4 REGISTRY
CN Carbamic acid, [[5-[[4,6-dideoxy-4-(methylamino)-3-O-.beta.-D-xylopyranosyl-.beta.-D-galactopyranosyl]oxy]-5,6,8,13-tetrahydro-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxobenzo[a]naphthacen-2-yl]carbonyl][2-(dimethylamino)-1-methyl-2-oxoethyl]-, phenylmethyl ester, [5S-[2(S*),5.alpha.,6.beta.]]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzo[a]naphthacene, carbamic acid deriv.
MF C50 H55 N3 O19
SR CA
LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 2-A

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 119:73091

L11 ANSWER 31 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 146173-25-3 REGISTRY
CN Carbamic acid, [(1,1-dioxido-2,3,4,5-thiophenetetrayl)tetrakis[4,1-

phenyleneazo(2-hydroxy-1,3-naphthalenediyl)carbonyl]]tetrakis-, tetra-2-thienyl ester (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Carbamic acid, [2,3,4,5-thiophenetetrayltetrakis[4,1-phenyleneazo(2-hydroxy-1,3-naphthalenediyl)carbonyl]]tetrakis-, tetra-2-thienyl ester, S,S-dioxide

MF C92 H56 N12 O18 S5

SR CA

LC STN Files: CA, CAPLUS

PAGE 1-A



PAGE 1-B



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 119:105802

L11 ANSWER 48 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 136138-32-4 REGISTRY
CN Carbamic acid, (2-fluoro-6-methoxybenzoyl)(2-iodophenyl)-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H15 F I N O4
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CHEMINFORMRX
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 115:159494

L11 ANSWER 50 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 134058-04-1 REGISTRY
CN Glycine, N-[[2-fluoro-6-methoxy-5-(trifluoromethyl)-1-naphthalenyl]carbonyl]-N-(methoxycarbonyl)-, 2-(diethylamino)-2-oxoethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H24 F4 N2 O7
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 115:91783

L11 ANSWER 52 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 134057-80-0 REGISTRY
CN Glycine, N-[(3,5-dibromo-6-methoxy-1-naphthalenyl)carbonyl]-N-(ethoxycarbonyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H15 Br2 N O6
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 115:91783

L11 ANSWER 53 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 131797-25-6 REGISTRY
CN Acetic acid, [[(3,6-dichloro-2-methoxybenzoyl)(methoxycarbonyl)amino]oxy]-, (2,4-dichlorophenyl)methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H15 Cl4 N O7
SR CA

LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 114:81247

L11 ANSWER 54 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 131777-77-0 REGISTRY
CN Acetic acid, [[(3,6-dichloro-2-methoxybenzoyl)(methoxycarbonyl)amino]oxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H17 Cl2 N O7
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 114:81247

L11 ANSWER 60 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 122670-87-5 REGISTRY
CN Glycine, N-[[2-bromo-6-methoxy-5-(trifluoromethyl)-1-naphthalenyl]carbonyl]-N-(ethoxycarbonyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H15 Br F3 N O6
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 115:91783

REFERENCE 2: 111:134749

L11 ANSWER 77 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 99468-84-5 REGISTRY
CN 1-Naphthalenesulfonic acid, 3-[(carboxyoctadecylamino)carbonyl]-4-hydroxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C30 H45 N O7 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 104:3120

L11 ANSWER 78 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 82083-60-1 REGISTRY
CN Benzenepropanoic acid, 4-methoxy-2-[[(methoxycarbonyl)methylamino]carbonyl]-.beta.-oxo-.alpha.-(phenylmethylene)-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H23 N O7
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 97:6594

L11 ANSWER 79 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 62050-96-8 REGISTRY
CN Carbamic acid, [[1-hydroxy-4-[[2-(1-oxopropyl)phenyl]azo]-2-naphthalenyl]carbonyl]phenyl-, hexadecyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C43 H53 N3 O5
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 86:131050

L11 ANSWER 80 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 36405-56-8 REGISTRY
CN Carbamic acid, (3-chloro-2,6-dimethoxybenzoyl)methoxy-, 1-methylethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N,2,6-Trimethoxy-N-isopropoxycarbonyl-3-chlorobenzamide
FS 3D CONCORD
MF C14 H18 Cl N O6
LC STN Files: BEILSTEIN*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 83:114023

REFERENCE 2: 81:3621

REFERENCE 3: 79:39343

REFERENCE 4: 76:153374

L11 ANSWER 81 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 36335-52-1 REGISTRY
CN Carbamic acid, (3-chloro-2,6-dimethoxybenzoyl)methoxy-, ethyl ester (9CI) (CA INDEX NAME)
OTHER NAMES:
CN N,2,6-Trimethoxy-N-ethoxycarbonyl-3-chlorobenzamide
FS 3D CONCORD
MF C13 H16 Cl N O6
LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 83:114023

REFERENCE 2: 81:3621

REFERENCE 3: 79:39343

REFERENCE 4: 76:153374

L11 ANSWER 82 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 33605-88-8 REGISTRY

CN Carbamic acid, (3,6-dichloro-2-ethoxybenzoyl)ethoxy-, propyl ester (8CI, 9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H19 Cl2 N O5
LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 81:169329

REFERENCE 2: 75:110065

L11 ANSWER 85 OF 85 REGISTRY COPYRIGHT 2003 ACS on STN
RN 314-66-9 REGISTRY
CN Carbamic acid, (3-fluoro-4-methoxybenzoyl)phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H12 F N O4
LC STN Files: CAOLD



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> d stat que
L3                STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE
L9          1293 SEA FILE=REGISTRY SSS FUL L3
L10               STR
```



```
VAR G1=X/OH/S/10/12/15/18
REP G2=(3-3) C
REP G3=(0-2) C
VAR G4=23/24/25/26/21
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  26

STEREO ATTRIBUTES: NONE
L11           85 SEA FILE=REGISTRY SUB=L9 SSS FUL L10
L12              STR
```



```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE

L13 1 SEA FILE=REGISTRY SUB=L11 SSS FUL L12
L14 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L13
L15 84 SEA FILE=REGISTRY ABB=ON PLU=ON L11 NOT L13
L16 20 SEA FILE=HCAPLUS ABB=ON PLU=ON L15
L18 1208 SEA FILE=REGISTRY ABB=ON PLU=ON L9 NOT L11
L19 85992 SEA FILE=REGISTRY ABB=ON PLU=ON PEPTIDE OR PEPTIDES
L21 25228 SEA FILE=REGISTRY ABB=ON PLU=ON HORMONE OR HORMONES OR POLYSACCHARIDE OR POLYSACCHARIDES OR MUCOPOLYSACCHARIDE OR MUCOPOLYSACCHARIDES OR CARBOHYDRATE OR CARBOHYDRATES OR LIPID OR LIPIDS OR INTERFERON OR INTERFERONS OR INTERLEUKIN OR INTERLEUKINS
L22 13723 SEA FILE=REGISTRY ABB=ON PLU=ON HEPARIN OR HEPARINS OR CALCITONIN OR ERYTHROPOIETIN? OR ANTIBOD? OR SOMATOSTATIN? OR ADRENOCORTICOTROPIN? OR OXYTOCIN? OR VASOPRESSIN? OR CROMOLYN? OR VANCOMYCIN? OR DESFERRIOXAMINE? OR ANTIBICROB? OR ANTIFUNG?
L23 209 SEA FILE=HCAPLUS ABB=ON PLU=ON L18
L24 536979 SEA FILE=HCAPLUS ABB=ON PLU=ON L19 OR PEPTIDE OR PEPTIDES
L25 1475315 SEA FILE=HCAPLUS ABB=ON PLU=ON L21 OR HORMONE OR HORMONES OR POLYSACCHARIDE OR POLYSACCHARIDES OR MUCOPOLYSACCHARIDE OR MUCOPOLYSACCHARIDES OR CARBOHYDRATE OR CARBOHYDRATES OR LIPID OR LIPIDS OR INTERFERON OR INTERFERONS OR INTERLEUKIN OR INTERLEUKINS
L26 601173 SEA FILE=HCAPLUS ABB=ON PLU=ON L22 OR HEPARIN OR HEPARINS OR CALCITONIN OR ERYTHROPOIETIN? OR ANTIBOD? OR SOMATOSTATIN? OR ADRENOCORTICOTROPIN? OR OXYTOCIN? OR VASOPRESSIN? OR CROMOLYN? OR VANCOMYCIN? OR DESFERRIOXAMINE? OR ANTIBICROB? OR ANTIFUNG?
L27 38 SEA FILE=HCAPLUS ABB=ON PLU=ON L23 AND (L24 OR L25 OR L26)
L28 37 SEA FILE=HCAPLUS ABB=ON PLU=ON L27 NOT (L14 OR L16)

=>
=>

=> d ibib abs hitrn l28 1-37

L28 ANSWER 1 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:301087 HCAPLUS
DOCUMENT NUMBER: 138:321579
TITLE: Reverse-turn mimetics for treatment of cancer
INVENTOR(S): Kahn, Michael; Eguchi, Masakatsu; Moon, Sung-Hwan; Chung, Jae-Uk; Lee, Sung-Chan; Jeong, Kwang-Won
PATENT ASSIGNEE(S): Choongwae Pharma Corporation, S. Korea
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031448	A1	20030417	WO 2002-KR1901	20021011

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,

TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-976470 A 20011012
US 2002-87443 A 20020301
OTHER SOURCE(S): MARPAT 138:321579
GI



I



II

AB Conformationally constrained compds. I [A is CHR3 or CO; B is CHR4 or CO; D is CHR5 or CO; E is -ZR6- or CO; G is -(XR7)n-, -CHR7NR8-, -CO(XR9)- or CO; W is Y-CO, CONH, SO2 or null; Y is O or S; X, Z are N or CH; n = 0 or 1; R1-R9 are amino acid chains] which mimic the secondary structure of reverse-turn regions of biol. active **peptides** and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Selected library compds. were assayed for oncogenic activity, e.g., triazinone deriv. II showed GI50 = 2.28 and 1.78 .mu.M against SW480 and HCT116 cells, resp.

IT **512853-02-0P**
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(reverse-turn mimetics for treatment of cancer)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 2 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:897060 HCAPLUS
DOCUMENT NUMBER: 139:90254
TITLE: Development of an injectable formulation of the novel platelet factor receptor antagonist, E5880
AUTHOR(S): Asai, Yasuyuki
CORPORATE SOURCE: Formulation Research Laboratory, Kawashima, Eisai Co., Ltd, Gifu, 501-6195, Japan
SOURCE: Yakuzaigaku (2002), 62(3), 124-131
CODEN: YAKUA2; ISSN: 0372-7629
PUBLISHER: Nippon Yakuzai Gakkai
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB An injectable formulation of E5880, a novel platelet activating factor receptor antagonist, was designated from the study of pH-stability, the

selection of excipient, and the relationship between moisture and stability. The physicochem. properties of E5880 micelles in the optimized formulation (0.6 mg/mL of E5880, 0.1% citric acid, 10% lactose, pH 2.8) were characterized. The crit. micelle concn. of E5880 in the formulation was 0.09 mg/mL, and the structure was spherical. The micellar size was approx. 5 nm and did not change before or after lyophilization and storage. The no. of mols. per micelle was 40. The micropolarity around the hydrocarbon region of the micelle was similar to that of butanol.

IT **128420-61-1**, E5880
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(development of injectable formulation of novel platelet factor receptor antagonist, E5880)

IT **63-42-3**, Lactose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(development of injectable formulation of novel platelet factor receptor antagonist, E5880)

L28 ANSWER 3 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:869496 HCAPLUS
DOCUMENT NUMBER: 137:363033
TITLE: Peptidomimetic modulators of cell adhesion
INVENTOR(S): Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie D.; Wang, Shoameng; Hu, Zenjian
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 309 pp., Cont.-in-part of U.S. Ser. No. 491,078.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002168761	A1	20021114	US 2001-769145	20010124

PRIORITY APPLN. INFO.: US 2000-491078 A2 20000124
OTHER SOURCE(S): MARPAT 137:363033

AB Peptidomimetics of cyclic **peptides**, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic **peptide** that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT **60482-96-4**, L-Leucine, L-arginyl-L-prolyl-L-tyrosyl-L-isoleucyl-**137833-31-9**, Myelopeptide 2 **255377-83-4**, Carbamic acid, [(2-oxo-2H-pyran-6-yl)carbonyl]-, phenyl ester
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptidomimetic modulators of cadherin-mediated cell adhesion for therapeutic use in relation to three-dimensional structure)

IT **475228-48-9 475228-49-0 475228-50-3 475228-51-4 475228-52-5 475228-53-6 475228-54-7 475228-56-9 475228-57-0**
RL: PRP (Properties)
(unclaimed protein sequence; peptidomimetic modulators of cell adhesion)

IT **110590-64-2**
RL: PRP (Properties)
(unclaimed sequence; peptidomimetic modulators of cell adhesion)

L28 ANSWER 4 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:293418 HCAPLUS
DOCUMENT NUMBER: 136:330549
TITLE: Topical antibiotic composition for treatment of eye infection
INVENTOR(S): Bandyopadhyay, Rebanta; Secreast, Pamela J.; Hawley, Leslie C.; McCurdy, Vincent E.; Tyle, Praveen; Bandyopadhyay, Paramita; Singh, Satish K.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030395	A1	20020418	WO 2001-US31590	20011010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001096753	A5	20020422	AU 2001-96753	20011010
EP 1324748	A1	20030709	EP 2001-977651	20011010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-239136P P 20001010
US 2001-285340P P 20010420
WO 2001-US31590 W 20011010
OTHER SOURCE(S): MARPAT 136:330549
AB There is provided a pharmaceutical compn. suitable for topical administration to an eye, the compn. comprising as active agent one or more oxazolidinone antibacterial drugs, for example linezolid, in a concn. effective for treatment and/or prophylaxis of a gram-pos. bacterial infection of the eye, and one or more ophthalmically acceptable excipient ingredients that reduce rate of removal of the compn. from the eye by lacrimation such that the compn. has an effective residence time in the eye of about 2 to about 24 h. The compn. is, for example, an in situ gellable soln., suspension or soln./suspension. Formulations contg. a gelling or mucoadhesive agent (xanthan gum, HPMC, poloxamer 407, and polycarbophil) resulted in significant amts. of linezolid being retained in the exterior of treated eyes 1 h or more after application.
IT **50-23-7**, Hydrocortisone **50-28-2**, Estradiol, biological studies **1404-90-6**, **Vancomycin 11138-66-2**, Xanthan gum **16110-51-3**, **Cromolyn 128420-61-1**, Minopafant
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical antibiotic compn. for treatment of eye infection)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 5 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:71873 HCAPLUS
DOCUMENT NUMBER: 136:123671
TITLE: Ophthalmic formulation of a selective cyclooxygenase-2

inhibitory drug
INVENTOR(S): Kararli, Tugrul T.; Bandyopadhyay, Rebanta; Singh, Satish K.; Hawley, Leslie C.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005815	A1	20020124	WO 2001-US22061	20010712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002035264	A1	20020321	US 2001-904098	20010712
EP 1303271	A1	20030423	EP 2001-953462	20010712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
US 2000-218101P P 20000713
US 2001-279285P P 20010328
US 2001-294838P P 20010531
US 2001-296388P P 20010606
WO 2001-US22061 W 20010712

OTHER SOURCE(S): MARPAT 136:123671

AB A pharmaceutical compn. suitable for topical administration to an eye contains a selective COX-2 inhibitor or nanoparticles of a drug of low water soly., at a concn. effective for the treatment and/or prophylaxis of a disorder in the eye, and 1 or more ophthalmically acceptable excipients that reduce rate of removal from the eye such that the compn. has an effective residence time of 2-24 h. Also provided is a method of treating and/or preventing a disorder in an eye, the method comprising administering to the eye a compn. of the invention. Thus, an ophthalmic nanoparticle suspension contained valdecoxib at 2.15 mg/g, 1.2% glycerin, 0.8% EDTA disodium salt, 4.0% Gelcarin GP-379NF, 0.21% SeaSpen PF and 0.82% Povidone.

IT **50-23-7**, Hydrocortisone **50-28-2**, Estradiol, biological studies **1404-90-6**, **Vancomycin 7585-39-9D**, .beta.-Cyclodextrin, hydroxypropyl ethers **9000-07-1**, Carrageenan **9012-76-4**, Chitosan **11138-66-2**, Xanthan gum **16110-51-3**, **Cromolyn 128420-61-1**, Minopafant
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ophthalmic formulation of cyclooxygenase-2 inhibitor pharmaceuticals)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 6 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:545724 HCAPLUS
DOCUMENT NUMBER: 135:147398
TITLE: Peptidomimetic modulators of cell adhesion
INVENTOR(S): Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie Denise; Wang, Shoameng; Hu, Zengjian
PATENT ASSIGNEE(S): Adherex Technologies, Inc., Can.
SOURCE: PCT Int. Appl., 416 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053331	A2	20010726	WO 2001-US2508	20010124
WO 2001053331	A3	20020711		
WO 2001053331	C2	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-491078 A 20000124
OTHER SOURCE(S): MARPAT 135:147398

AB Peptidomimetics of cyclic **peptides**, and compns. comprising such peptidomimetics are provided. The peptidomimetics have a three-dimensional structure that is substantially similar to a three-dimensional structure of a cyclic **peptide** that comprises a cadherin cell adhesion recognition sequence HAV. Methods for using such peptidomimetics for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.

IT **60482-96-4 137833-31-9**, Myelopeptide 2
255377-83-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptidomimetic modulators of cell adhesion)

IT **110590-64-2**
RL: PRP (Properties)
(unclaimed sequence; peptidomimetic modulators of cell adhesion)

L28 ANSWER 7 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:214224 HCAPLUS
DOCUMENT NUMBER: 135:266957
TITLE: Role of Platelet-Activating Factor in Hepatectomy with Pringle's Maneuver
AUTHOR(S): Gu, Mei; Takada, Yasutsugu; Fukunaga, Kiyoshi; Ishiguro, Shingo; Taniguchi, Hideki; Seino, Kenichiro; Yuzawa, Kenji; Otsuka, Masaaki; Todoroki, Takeshi; Fukao, Katashi
CORPORATE SOURCE: Department of Surgery, Institue of Clinical Medicine, University of Tsukuba, Tsukuba City, Ibaraki, 305-8575, Japan
SOURCE: Journal of Surgical Research (2001), 96(2), 233-238
CODEN: JSGRA2; ISSN: 0022-4804
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Background. Interruption of hepatic inflow is commonly used to reduce blood loss during extensive liver resection, but may cause liver dysfunction. The present study investigated the effects of platelet-activating factor (PAF) antagonist E5880 on total liver warm ischemia and 70% hepatectomy. Methods. Rabbits were used in this study and were divided into four groups: group 1, those treated with only 70%

hepatectomy; group 2, those treated with only 20 min Pringle's maneuver; group 3, those treated with both Pringle's maneuver and 70% hepatectomy without pretreatment; and group 4, those pretreated with PAF antagonist E5880 (0.3 mg/kg) followed by Pringle's maneuver and 70% hepatectomy. The remnant liver function was then evaluated after reperfusion. Results. Seven-day survival rates in both groups 1 and 2 were 100%. E5880 treatment significantly increased 7-day survival rate (group 4: 38% vs. group 3: 0%, $P < 0.05$) after a combination of Pringle's maneuver and 70% hepatectomy. The elevations of serum liver enzymes (GOT, GPT, mGOT, and LDH) were significantly inhibited in group 4 at 1 and 4 h after reperfusion. Portal venous pressure and the energy charge of liver were also significantly improved in group 4, compared with those in group 3. Endothelin-1 levels of arterial and portal venous blood progressively increased after reperfusion; however, there were no significant differences between the two groups. Leukocyte infiltration into the liver was significantly inhibited in group 4. Conclusion. E5880 pretreatment has protective effects on liver function after 70% hepatectomy with Pringle's maneuver in rabbits. (c) 2001 Academic Press.

IT **65154-06-5**, Platelet-activating factor
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(role of platelet-activating factor in hepatectomy with Pringle's maneuver)

IT **128420-61-1**, E5880
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(role of platelet-activating factor in hepatectomy with Pringle's maneuver)

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 8 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:167792 HCAPLUS
DOCUMENT NUMBER: 134:227363
TITLE: Topical use of kappa opioid agonists to treat otic pain
INVENTOR(S): Gamache, Daniel A.; Yanni, John M.
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015678	A2	20010308	WO 2000-US22766	20000818
WO 2001015678	A3	20020103		

W: AU, BR, CA, CN, JP, MX, PL, TR, ZA
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1999-387359 A 19990831

AB Topical or intranasal compns. and methods for treating otic pain caused by otitis, surgery, or swimmer's ear are disclosed. In particular, the invention discloses compns. and methods of using .kappa.-opioid agonists locally for the prevention or alleviation of otic pain. Compns. also comprise antimicrobial, antiallergy, and anti-inflammatory agents to treat otic infections, allergies, and inflammations assocd. with otic pain. For example, an otic/nasal soln. contained (by wt.) a .kappa.-opioid EMD-61753 0.01-1.0%, phosphate buffered saline 1.0%, Polysorbate 80 0.5%, and water up to 100%.

IT **65154-06-5**, Platelet-activating factor

RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonists; topical compns. contg. .kappa.-opioid agonists for treatment of otic pain)

IT **1404-90-6, Vancomycin 16110-51-3, Cromolyn 128420-61-1**, Minopafant
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical compns. contg. .kappa.-opioid agonists for treatment of otic pain)

L28 ANSWER 9 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:167791 HCAPLUS
DOCUMENT NUMBER: 134:227362
TITLE: Use of 5-HT1B/1D agonists to treat otic pain
INVENTOR(S): Gamache, Daniel A.; Yanni, John M.; Sharif, Najam A.
PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015677	A2	20010308	WO 2000-US22764	20000818
WO 2001015677	A3	20020328		

W: AU, BR, CA, CN, JP, MX, PL, TR, US, ZA
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: US 1999-387358 A 19990831

AB Topical otic or intranasal compns. and methods for treating otic pain caused by otitis, surgery, or swimmer's ear are disclosed. In particular, the invention discloses compns. and methods of using 5-HT1B/1D agonists for the prevention or alleviation of otic pain. Compns. also comprise an antimicrobial, antiallergy, and anti-inflammatory agent to treat otic infections, allergies, and inflammations assocd. with otic pain. For example, an otic/nasal soln. contained CGS-12066A 0.01-1.0%, phosphate buffered saline 1.0%, Polysorbate 80 0.5%, and water up to 100% (wt./vol.), resp.

IT **65154-06-5**, PAF
RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonists; topical compns. of 5-HT1B/1D agonists for treatment of otic pain)

IT **1404-90-6, Vancomycin 7585-39-9D**, .beta.-Cyclodextrin, ethers with propanediol **9004-62-0**, Hydroxyethyl cellulose **16110-51-3, Cromolyn 128420-61-1**, Minopafant
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (topical compns. of 5-HT1B/1D agonists for treatment of otic pain)

L28 ANSWER 10 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:771045 HCAPLUS
DOCUMENT NUMBER: 134:275524
TITLE: Pharmacologic graft protection without donor pretreatment in liver transplantation from non-heart-beating donors
AUTHOR(S): Gu, Mei; Takada, Yasutsugu; Fukunaga, Kiyoshi; Ishiguro, Shingo; Taniguchi, Hideki; Seino, Kenichiro; Yuzawa, Kenji; Otsuka, Masaaki; Todoroki, Takeshi; Fukao, Katashi
CORPORATE SOURCE: Department of Surgery, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, 305-8575, Japan
SOURCE: Transplantation (2000), 70(7), 1021-1025

CODEN: TRPLAU; ISSN: 0041-1337
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Non-heart-beating donors (NHBDs) are considered potential sources of transplant organs in an effort to alleviate the problem of donor shortage in clin. liver transplantation. The authors investigated the possibility of pharmacol. protection of hepatic allograft function from NHBDs without donor pretreatment. Orthotopic liver transplantation was performed using swine. In donors, cardiac arrest was induced by stopping the respirator. 45 Min after cessation of the respirator, the liver was flushed with cold lactated Ringer's soln. including **heparin** and with the University of Wisconsin (UW) soln., and then preserved for 8 h at 4.degree.C in the UW soln. The swine were divided into 2 groups: a control group and a treated group. In the treated group, an endothelin antagonist TAK-044 was added to the UW solns. (10 mg/L), and TAK-044 (10 mg/kg body wt.) and a platelet activating factor antagonist E5880 (0.3 mg/kg body wt.) were also administered to the recipients. TAK-044 and E5880 treatment significantly increased the 7-day survival rate of the recipients (100% vs. 17%, P<0.05). In the treated group, portal venous pressure immediately after reperfusion of the graft was significantly lower than in the control group, and postoperative increase in serum concns. of glutamic oxaloacetic transaminase and total bilirubin was attenuated. Moreover, the energy charge and ATP concn. of the liver were rapidly restored after reperfusion. Pharmacol. modulation with TAK-044 and E5880 avoiding donor pretreatment can improve the viability of hepatic allografts procured from NHBDs.

IT **128420-61-1**, E5880 **157380-72-8**, TAK-044
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. graft protection without donor pretreatment in liver transplantation)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 11 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:144900 HCAPLUS
DOCUMENT NUMBER: 132:194661
TITLE: Preparation of ring modified cyclic **peptide** analogs as **antifungal** agents
INVENTOR(S): Borromeo, Peter Stanley; Cohen, Jeffrey Daniel; Gregory, George Stuart; Henle, Stacy Kay; Hitchcock, Stephen Andrew; Jungheim, Louis Nickolaus; Mayhugh, Daniel Ray; Shepherd, Timothy Alan; Turner, William Wilson, Jr.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000011023	A2	20000302	WO 1999-US18908	19990818
WO 2000011023	A3	20000615		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2340676	AA	20000302	CA 1999-2340676	19990818
AU 9955726	A1	20000314	AU 1999-55726	19990818
EP 1107981	A2	20010620	EP 1999-942321	19990818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002528388	T2	20020903	JP 2000-566295	19990818

PRIORITY APPLN. INFO.: US 1998-97228P P 19980820
WO 1999-US18908 W 19990818

OTHER SOURCE(S): MARPAT 132:194661
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A method is provided for modifying the cyclic **peptide** ring system of echinocandin-type compds. to produce new analogs, e.g., I (R = alkyl, alkenyl, alkynyl, aryl, heteroaryl; R1, R4 = H, OH; R2 = H, Me; R3 = H, Me, CH2CONH2, CH2, CH2NH2; R5 = OH, OPO3H2, OSO3H; R6 = H, OSO3H), having **antifungal** activity. The process comprises opening the cyclic **peptide** ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic **peptide** ring structure. Thus, cyclic **peptide** II [R = p-(pentyloxy)-p-terphenyl] was prepd. and showed min. inhibitory concns. 0.005-0.156 .mu.g/mL against four fungi.

IT **259825-46-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of ring modified cyclic **peptide** analogs as **antifungal** agents)

IT **79404-91-4**, Cilofungin
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of ring modified cyclic **peptide** analogs as **antifungal** agents)

IT **259824-70-9P 259824-73-2P 259824-82-3P**
259825-05-3P 259825-11-1P 259825-12-2P
259825-24-6P 259825-25-7P 259825-33-7P
259825-39-3P 259825-54-2P 259825-61-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of ring modified cyclic **peptide** analogs as **antifungal** agents)

L28 ANSWER 12 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:576914 HCAPLUS
DOCUMENT NUMBER: 131:228727
TITLE: Preparation of pyridazine derivatives as **interleukin** 1.beta. production inhibitors
INVENTOR(S): Ohkuchi, Masao; Kyotani, Yoshinori; Shigyo, Hiromichi; Yoshizaki, Hideo; Koshi, Tomoyuki; Kitamura, Takahiro; Matsuda, Takayuki; Oda, Soichi; Habata, Yuriko; Kotaki, Kyoko
PATENT ASSIGNEE(S): Kowa Co., Ltd., Japan; et al.
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9944995	A1	19990910	WO 1999-JP925	19990226
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2321254	AA	19990910	CA 1999-2321254	19990226
AU 9926414	A1	19990920	AU 1999-26414	19990226
AU 739431	B2	20011011		
EP 1061077	A1	20001220	EP 1999-906509	19990226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 506144	A	20011130	NZ 1999-506144	19990226
US 6403586	B1	20020611	US 2000-622897	20000831
NO 2000004353	A	20000901	NO 2000-4353	20000901

PRIORITY APPLN. INFO.: JP 1998-49396 A 19980302
WO 1999-JP925 W 19990226

GI



I

AB The title compds. I [R1 represents lower alkoxy, lower alkylthio or halogeno; R2 represents H, lower alkoxy, lower alkylthio or halogeno; R3 represents OH, CN, halogeno, lower cycloalkyl, lower alkyl or lower alkenyl optionally substituted by an optionally substituted arom. group or optionally substituted carbamoyl; R4 represents COOH, lower alkoxycarbonyl, optionally substituted carbamoyl, optionally substituted amino or optionally substituted ureido; and the dotted line means a single bond or a double bond between the carbon atoms at the 4- and 5-positions] are prepd. I are useful as preventives/remedies for immunol. diseases, inflammatory diseases, ischemic diseases, etc. In an in vitro test using cells, 2-cyclopropylmethyl-6-(4-methoxyphenyl)-4-methylcarbamoyl-2H-pyridazin-3-one showed IC50 of 0.038 .mu.M against lipopolysaccharide-induced **interleukin** 1 .beta. prodn.

IT **243862-55-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridazine derivs. as **interleukin** 1.beta. prodn.

inhibitors)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 13 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:198291 HCAPLUS
DOCUMENT NUMBER: 131:13296
TITLE: Quantitative determination of E5880 in rat plasma by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry
AUTHOR(S): Kikuchi, Kiyomi; Sano, Yoshihisa; Taniguchi, Sachie; Matsui, Kenji; Namiki, Masayuki; Ito, Hatsue; Sakurai, Hideki; Yoshimura, Tsutomu
CORPORATE SOURCE: Tsukuba Research Laboratories, Eisai Co. Ltd., Tsukuba, 300-2635, Japan
SOURCE: Journal of Mass Spectrometry (1999), 34(2), 93-97
CODEN: JMSPFJ; ISSN: 1076-5174
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A simple and sensitive method is described for the detn. of E5880 in rat plasma. The method is based on high-performance liq. chromatog./electrospray ionization mass spectrometry, using deuterated E5880 as an internal std. Selected reaction monitoring is employed for selectivity and sensitivity, this in turn enables quantification in a short period of time (within 7 min) over the extended range of 0.1-1000 ng/mL with acceptable precision and accuracy. The method demonstrated to be suitable for the quant. anal. of E5880 in rat plasma. The pharmacokinetic profile of E5880 after a single i.v. administration of E5880 was elucidated.
IT **128420-61-1**, E5880
RL: ANT (Analyte); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(quant. detn. of E5880 in rat plasma by high-performance liq. chromatog./electrospray ionization tandem mass spectrometry)
IT **226087-56-5**
RL: ARU (Analytical role, unclassified); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(quant. detn. of E5880 in rat plasma by high-performance liq. chromatog./electrospray ionization tandem mass spectrometry)
IT **65154-06-5**, Blood platelet-activating factor
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(quant. detn. of E5880 in rat plasma by high-performance liq. chromatog./electrospray ionization tandem mass spectrometry)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 14 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:64781 HCAPLUS
DOCUMENT NUMBER: 130:125100
TITLE: Preparation of 6-azauracil derivatives as IL-5 biosynthesis inhibitors
INVENTOR(S): Freyne, Eddy Jean Edgard; Boeckx, Gustaaf Maria; Van Wauwe, Jean Pierre Frans; Diels, Gaston Stanislas Marcella
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902504	A1	19990121	WO 1998-EP4192	19980702
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9884413	A1	19990208	AU 1998-84413	19980702
AU 756637	B2	20030116		
EP 1003729	A1	20000531	EP 1998-935022	19980702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
EE 9900585	A	20000815	EE 1999-585	19980702
BR 9811499	A	20000919	BR 1998-11499	19980702
NZ 501627	A	20020201	NZ 1998-501627	19980702
JP 2002508001	T2	20020312	JP 1999-508127	19980702
ZA 9806095	A	20000110	ZA 1998-6095	19980709
NO 2000000094	A	20000308	NO 2000-94	20000107
US 2002042416	A1	20020411	US 2001-855068	20010514

PRIORITY APPLN. INFO.: EP 1997-202117 A 19970710
WO 1998-EP4192 W 19980702
US 2000-462323 B1 20000105

OTHER SOURCE(S): MARPAT 130:125100
GI



II

AB RZCR1R2R3 [I; R = 3,5-dioxo-1,2,4-triazin-2(3H)-yl; R1 = H, alkyl, alkoxy, (hetero)aryl, etc.; R2 = cyano or C(:X)YR5; R3 = (un)substituted Ph; R5 = H, (ar)alkyl, (hetero)aryl, etc.; X = O or S; Y = bond, O, S, NR6; R6 = H, alkyl(oxy), aralkyl; Z = (un)substituted phenylene] were prepd. Thus, 4,3-Cl(F3C)C6H3CH2CN was arylated by 1,2,3-trichloro-5-nitrobenzene and the .alpha.-methylated product reduced to give methylphenylbenzeneacetonitrile II (R = NH2) which was diazotized and the product condensed with NCCH2CONHCO2Et to give II [R = NHN:C(CN)CONHCO2Et]. The latter was cyclized and the product converted in 2 steps to II [R = 3,5-dioxo-1,2,4-triazin-2(3H)-yl]. Data for biol. activity of I were given.

IT **219909-76-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 6-azauracil derivs. as IL-5 biosynthesis inhibitors)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 15 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:787765 HCAPLUS
DOCUMENT NUMBER: 130:191586
TITLE: Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist
AUTHOR(S): Takada, Y.; Fukunaga, K.; Taniguchi, H.; Yuzawa, K.; Otsuka, M.; Fukao, K.
CORPORATE SOURCE: Department of Surgery, Institute of Clinical Medicine, Tsukuba University, Tsukuba, 305, Japan
SOURCE: Transplantation Proceedings (1998), 30(7), 3694-3695
CODEN: TRPPA8; ISSN: 0041-1345
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To investigate the possibility of pharmacol. modulation of hepatic allograft function from graft procurement from non-heart-beating donors (NHBD), the effects of treatment with FK506 and a platelet activating factor (PAF) antagonist were evaluated in relation to changes in hepatic adenine nucleotide metab. in porcine orthotopic liver transplantation (LTx). The present study suggests that FK506 and the PAF antagonist E5880 can improve the function of grafts subjected to prolonged warm ischemia in NHBD, and that the protective effect of FK506 is time dependent. Although the exact mechanism has yet to be clarified, the protective effects of the two drugs are synergistic, and combined treatment with these agents has the most beneficial effect on graft function, indicating a potential for use in clin. LTx from NHBD.
IT **128420-61-1**, E5880
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(energy metab. of hepatic allografts subjected to prolonged warm ischemia and pharmacol. modulation with FK506 and platelet activating factor antagonist)
IT **65154-06-5**, Platelet-activating factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(energy metab. of hepatic allografts subjected to prolonged warm ischemia and pharmacol. modulation with FK506 and platelet activating factor antagonist)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 16 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:35982 HCAPLUS
DOCUMENT NUMBER: 126:157369
TITLE: Design, synthesis and bioactivities of heterocyclic **lipids** as platelet activating factor antagonists
AUTHOR(S): Chung, Sung-Kee; Ban, Su Ho; Kim, Si Hwan; Woo, Soon Hyung
CORPORATE SOURCE: Dep. Chem., Pohang Univ. Sch. Technol. Res. Inst. Ind. Sci. Technol., Pohang, 790-784, S. Korea
SOURCE: Korean Journal of Medicinal Chemistry (1996), 6(2), 294-302
CODEN: KJMCE7; ISSN: 1225-0058
PUBLISHER: Korean Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III

AB Title compds. such as I [X = (CH2)n, n = 1-4; O, AcN], II [X = CH2CH2, O, S; T = CO; n = 4, 5; N(Het) = pyridine, thiazole, quinoline], and III (X = CH2, O, S, NAc, NBz; Y = Cl, I) were prepd. and tested for their ability to displace [3H]-PAF from its receptor in rabbit platelet membranes and to inhibit PAF-induced aggregation of rabbit platelets.

IT **156719-77-6P 156719-78-7P 156719-80-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(heterocyclic **lipids** as platelet activating factor antagonists)

IT **65154-06-5**, Blood platelet-activating factor
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(heterocyclic **lipids** as platelet activating factor antagonists)

L28 ANSWER 17 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1996:316586 HCAPLUS
DOCUMENT NUMBER: 125:48744
TITLE: Prevention of cerebrovasospasm following subarachnoid hemorrhage in rabbits by the platelet-activating factor antagonist, E5880
AUTHOR(S): Hirashima, Yutaka; Endo, Shunro; Kato, Ryoko; Takaku, Akira
CORPORATE SOURCE: Department Neurosurgery, Toyama Medical and Pharmaceutical University, Toyama, Japan
SOURCE: Journal of Neurosurgery (1996), 84(5), 826-830
CODEN: JONSAC; ISSN: 0022-3085
PUBLISHER: American Association of Neurological Surgeons
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Recently, an important role of platelet-activating factor (PAF), an inflammation mediator, has been demonstrated in the genesis of cerebral vasospasm following subarachnoid hemorrhage (SAH). In the current study, the authors examd. whether i.v. administration of the novel PAF antagonist, E5880, can prevent vasospasm following SAH in rabbits. A vasospasm model was produced in three groups of rabbits using two

subarachnoid injections of autologous arterial blood, followed by i.v. administration of distd. water (control), a low dose of E5880 (0.1 mg/kg in distd. water), or a high dose of E5880 (0.5 mg/kg in distd. water). Neurol. deterioration was largely prevented in the rabbits that received E5880. Basilar artery constriction was also reduced by both doses of E5880. Histol. examn. at autopsy predominantly showed ischemic changes in the brain. Animals in each E5880-treated group exhibited ischemic changes less frequently than those in the control group. Plasma thromboxane B2 concns. were reduced in rabbits treated with E5880. Platelet-activating factor was immunolocalized in the intima and media of the basilar artery in the control group. The PAF immunoreactivity demonstrated in the basilar artery was decreased in the E5880 groups in a dose-dependent manner. Thus, this study provides evidence that PAF may play a role in the pathogenesis of vasospasm after SAH and that i.v. administration of E5880 is a promising approach in preventing vasospasm.

IT **65154-06-5**, Platelet-activating factor
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(prevention of cerebrovasospasm following subarachnoid hemorrhage in rabbits by platelet-activating factor antagonist E5880 in relation to plasma thromboxane B2 concns.)

IT **128420-61-1**, E5880
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prevention of cerebrovasospasm following subarachnoid hemorrhage in rabbits by platelet-activating factor antagonist E5880 in relation to plasma thromboxane B2 concns.)

L28 ANSWER 18 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1996:22564 HCAPLUS
DOCUMENT NUMBER: 124:202845
TITLE: Heterocyclic **lipids** with PAF antagonist activities 5. Synthesis of 2,4-bis(hydroxymethyl)-thietane and -azetidine derivatives
AUTHOR(S): Chung, Sung-Kee; Ban, Su Ho; Kim, Si Hwan; Woo, Soon Hyung
CORPORATE SOURCE: Dep. of Chemistry, Pohang Univ. of Science and Technology, Pohang, 790-784, S. Korea
SOURCE: Korean Journal of Medicinal Chemistry (1995), 5(2), 112-24
CODEN: KJMCE7; ISSN: 1225-0058
PUBLISHER: Korean Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Conformationally constrained analogs of platelet activating factor incorporating a lipophile and a pyridine-like heterocycle coupled to core groups such as 2,4-bis(hydroxymethyl)thietanes I [X = S] and II and -azetidines I [X = NR, R = Ac, Bz, CH2Ph] through hydrogen bond accepting linkages such as ether and carbamate have been synthesized as potent PAF receptor antagonists.

IT **65154-06-5**, Platelet activating factor
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(antagonist; prepn. of heterocyclic **lipids** with PAF antagonist activities)

IT **156720-40-0P 156720-41-1P 156720-45-5P 156720-74-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocyclic **lipids** with PAF antagonist activities)

IT **156719-77-6P 156719-78-7P 156719-80-1P 156719-93-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of heterocyclic **lipids** with PAF antagonist activities)

L28 ANSWER 19 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1996:12197 HCAPLUS
DOCUMENT NUMBER: 124:203052
TITLE: New methods for solid phase **peptide** synthesis of transition-state analog inhibitors of HIV-1 protease and DPP-IV
AUTHOR(S): Piron, Jan; Tourwe, Dirk
CORPORATE SOURCE: Org. Chem., Free Univ. Brussels, Brussels, B-1050, Belg.
SOURCE: Letters in Peptide Science (1995), 2(3/4), 229-32
CODEN: LPSCEM; ISSN: 0929-5666
PUBLISHER: ESCOM
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new and stereoselective method to synthesize hydroxyethylamine and hydroxymethylamide **peptide** bond isosteres is developed. The key step is the addn. of 2-trimethylsilylthiazole to .alpha.-amino aldehydes,

followed by transformation to .alpha.-hydroxy-.beta.-amino aldehydes. The stereochem. of the addn. can be manipulated by the choice of the nitrogen substitution. The isosteres are easily synthesized via solid-phase **peptide** synthesis, which rapidly gives the desired pseudopeptides.

IT **174147-83-2P 174147-84-3P 174147-85-4P**
174290-78-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(solid-phase prepn. of hydroxyethylamine and hydroxymethylamide transition-state analog protease inhibitors)

L28 ANSWER 20 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:598395 HCAPLUS
DOCUMENT NUMBER: 123:314308
TITLE: Synthesis and bioactivities of heterocyclic **lipids** as PAF antagonists. 2
AUTHOR(S): Chung, S. K.; Ban, S. H.; Kim, S. H.; Kim, B. E.; Woo, S. H.
CORPORATE SOURCE: Dep. Chemistry, Pohang Univ. Science Technolog, Pohang, 790-784, S. Korea
SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(10), 1097-102
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Conformationally constrained analogs of platelet activating factor (PAF) incorporating a lipophile and a pyridine-like heterocycle linked to core groups such as 1,1-bis(hydroxymethyl)cyclobutane and 2,4-bis(hydroxymethyl)-oxetane, -thietane and -azetidine skeletons, e.g. I (X = O, S, NAc, NBz), via hydrogen bond acceptors such as ether and/or carbamate have been synthesized, and their in vitro and in vivo bioactivities have indicated potent and selective PAF antagonism.

IT **65154-06-5**, Platelet activating factor
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and bioactivities of heterocyclic **lipids** as platelet activating factor antagonists)

IT **156719-77-6P 156719-78-7P 156719-80-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and bioactivities of heterocyclic **lipids** as platelet activating factor antagonists)

L28 ANSWER 21 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:387277 HCAPLUS
DOCUMENT NUMBER: 122:182582
TITLE: Effects of platelet-activating factor antagonist on preservation/reperfusion injury of the graft in

porcine orthotopic liver transplantation

AUTHOR(S): Takada, Yasutsugu; Boudjema, Karim; Jaeck, Daniel; Bel-Haouari, Mohammed; Doghmi, Mustapha; Chenard, Marie-Pierre; Wolf, Philippe; Cinqualbre, Jacques

CORPORATE SOURCE: Laboratoire de Chirurgie Experimentale, Fondation Transplantation, Strasbourg, 67200, Fr.

SOURCE: Transplantation (1995), 59(1), 10-16
CODEN: TRPLAU; ISSN: 0041-1337

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To investigate the role of platelet-activating factor (PAF) in the preservation/reperfusion injury of the liver graft, the effect of treatment with a potent PAF antagonist (E5880) was evaluated in a pig orthotopic liver transplantation model. The graft liver was flushed out and preserved for 8 h at 4.degree. using a simplified Univ. of Wisconsin (UW) soln. The PAF antagonist was administered into the UW soln. (1 mg/L), into the rinsing soln. (1 mg/L), and to a recipient pig (0.3 mg/kg d.i.v.) in group 1. The PAF antagonist was not given in the control group (group 2). Postoperative survival of >12 h was 100% (9/9) in group 1 and 56% (5/9) in group 2. At 12 h after reperfusion of the graft (RPF), the arterial ketone body ratio (acetoacetate to 3-hydroxybutyrate) increased to 1.54 in group 1, compared with 0.95 in group 2. In group 2, blood leukocyte count decreased to 8.3 .times. 103/.mu.L at 2 h after RPF, in contrast to a slight increase in group 1 (14.3 .times. 103/.mu.L). At 4 h after RPF, glutamic oxaloacetic transaminase (461 vs. 712 U/L), glutamic pyruvic transaminase (65 vs. 82 U/L), and the lactate level (6.2 vs. 9.4 mmol/L) in arterial blood were significantly lower in group 1 than in group 2. Light and electron microscopic study at 1 h after RPF showed neutrophil sludging in the sinusoids and sinusoidal endothelial cell damage in group 2, while these findings were attenuated in group 1. It is suggested that PAF plays a key role in microcirculatory disturbance of the liver graft manifested on reperfusion, and that the treatment with E5880 has a protective effect against preservation/reperfusion injury of the graft in liver transplantation.

IT **65154-06-5**, Platelet-activating factor **128420-61-1**, E5880
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(platelet-activating factor antagonist effects on preservation/reperfusion injury in liver transplantation)

L28 ANSWER 22 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1994:533939 HCAPLUS

DOCUMENT NUMBER: 121:133939

TITLE: Preparation of bis(carbamoyloxymethyl)thietanes and analogs as PAF antagonists

INVENTOR(S): Woo, Soon Hyung; Chung, Sung Kee; Ban, Soo Ho; Kim, Si Hwan

PATENT ASSIGNEE(S): Pohang Iron and Steel Co., Ltd., S. Korea; Research Institute of Industrial Science and Technology

SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9400447	A1	19940106	WO 1993-KR53	19930630
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
KR 9513770	B1	19951115	KR 1992-11554	19920630

KR 9615088	B1	19961024	KR 1993-5778		19930407
EP 607374	A1	19940727	EP 1993-913613		19930630
EP 607374	B1	19990407			
R: CH, DE, ES, FR, GB, LI					
JP 06510306	T2	19941117	JP 1994-502213		19930630
ES 2130274	T3	19990701	ES 1993-913613		19930630
US 5610310	A	19970311	US 1995-476642		19950607
US 5700817	A	19971223	US 1995-553843		19951106

PRIORITY APPLN. INFO.:

KR 1992-11554	A	19920630
KR 1993-5778	A	19930407
WO 1993-KR53	W	19930630
US 1994-193163	B3	19940210

OTHER SOURCE(S): MARPAT 121:133939

GI



I

AB R1OCH2CHRCH2CHRCH2OR2 and (RCH2)2C(CH2OR1)CH2OR2 [R2 = O, SO0-2, CH2, (alky)amino, etc.; R1 = alk(en)yl, alkynyl, CONH2, etc.; R2 = T(CH2)nV X-q; T = bond, CO, CO2, CONH, etc.; V = cyclic ammonio, N+R5R6R7, N-alkylpyridinium-2-yl; R5-R7 = alkyl; X- = halide, alkanesulfonate, carboxylate, etc.; n = 1-10; q = 0 or 1] were prepd. Thus, CH2(CHBrCO2Me)2 was cyclocondensed with Na2S and the reduced product converted in 5 steps to title compd. I which had IC50 of 0.021.mu.M against PAF-induced platelet aggregation in vitro.

IT **65154-06-5**, PAF
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonists of, bis(carbamoyloxymethyl)thietanes and analogs as)

IT **156720-40-0P 156720-41-1P 156720-45-5P 156720-74-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of PAF antagonist)

IT **156719-77-6P 156719-78-7P 156719-80-1P 156719-93-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as PAF antagonist)

L28 ANSWER 23 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	1994:289271 HCAPLUS
DOCUMENT NUMBER:	120:289271
TITLE:	Radioimmunoassay for the Novel Platelet Activating Factor Receptor Antagonist E5880
AUTHOR(S):	Suzuki, Hiromasa; Asano, Osamu; Tadano, Kyoichi; Horie, Toru
CORPORATE SOURCE:	Tsukuba Research Laboratories, Eisai Co. Inc., Tsukuba, 300-26, Japan
SOURCE:	Journal of Pharmaceutical Sciences (1994), 83(5), 657-61 CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB A direct RIA for E5880, 1-ethyl-2-[[N-(2-methoxybenzoyl)-N-[[(2R)-2-methoxy-3-[[[4-[(octadecylcarbamoyl)oxy]piperidino]carbonyl]oxy]propoxy]carbonyl]amino]methyl]pyridinium chloride, a novel analog-type antagonist of

platelet activating factor (PAF), was developed. In this procedure, [3H]E5880 was used as the radioligand, and the antiserum was obtained from rabbits immunized with hapten covalently bound to bovine serum albumin. The hapten represents a structural analog of E5880, with a carboxyl group on the terminal carbon of the 3-position side chain. A metabolite of E5880, deacyl-E5880, cross-reacted weakly (1.8%) with this antiserum. The assay buffer for the RIA consisted of PBS, pH 6.5, contg. 1% BSA to prevent the degrdn. of E5880 in aq. soln. and its adsorption to the tube. The detection limit of the assay was 200 pg/mL when a 0.1-mL plasma sample was used. The RIA was used for the direct anal. of E5880 in dog plasma. The validity of the RIA in dog plasma was demonstrated by comparative anal. of a no. of samples by HPLC ($r = 0.995$, slope = 0.9425). The RIA was also used to det. the pharmacokinetics of E5880 in the dog. After the i.v. administration of E5880 (0.2 mg/kg), plasma levels declined biexponentially. The initial plasma half-life, including the distribution phase, was 0.26 h, and the plasma half-life of elimination was 9.96 h.

IT **128420-61-1**, E5880
RL: ANST (Analytical study)
(detn. in blood by RIA and pharmacokinetics of)

IT **153735-22-9DP**, conjugates with serum albumins
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and **antibodies** formation from, for RIA of platelet activating factor receptor antagonist E5880)

IT **153735-21-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for RIA of platelet activating factor receptor antagonist E5880)

IT **153735-20-7**
RL: ANST (Analytical study)
(reaction with tritiated octadecylamine and quaternization with iodomethane of)

L28 ANSWER 24 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1994:188554 HCAPLUS
DOCUMENT NUMBER: 120:188554
TITLE: Potential etiologic role of PAF in two major septic complications; disseminated intravascular coagulation and multiple organ failure
AUTHOR(S): Ou, M. C.; Kambayashi, J.; Kawasaki, T.; Uemura, Y.; Shinozaki, K.; Shiba, E.; Sakon, M.; Yukawa, M.; Mori, T.
CORPORATE SOURCE: Med. Sch., Osaka Univ., Suita, 565, Japan
SOURCE: Thrombosis Research (1994), 73(3-4), 227-38
CODEN: THBRAA; ISSN: 0049-3848
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A possible role of platelet-activating factor (PAF) in the occurrence of the two septic complications, i.e., disseminated intravascular coagulation (DIC) and multiple organ failure (MOF) was investigated, employing a rabbit model and a novel PAF antagonist E5880. By an instillation of fecal suspension into the common bile duct of the rabbit, manifestations of DIC and MOF were obsd. with high reproducibility by 9 h after the septic insult. E5880 was i.v. administered to 12 rabbits for 1 h after the septic insult at dose of 1 mg/kg (n=6) or 3mg/kg (n=6). All the rabbits were subjected to observation of vital signs and serial detn. of lab. tests for 9 h and then lung, liver and kidney were removed for histol. examn. Blood endotoxin level increased significantly by 9 h after the septic insult. Although administration of E5880 did not affect the endotoxemia, the antagonist attenuated in a dose related manner lab. manifestation of DIC such as thrombocytopenia and prolonged prothrombin time as well as that of MOF such as increase in serum bilirubin and creatinine level. The beneficial effect of E5880 on MOF was also confirmed by the histol. evaluation. These observations indicated that

PAF is deeply involved in the occurrence of DIC and MOF due to sepsis and E5880 may be one of the modalities to treat or prevent these two major septic complications.

IT **65154-06-5**, Platelet-activating factor
RL: BIOL (Biological study)
(in sepsis induced disseminated intravascular coagulation and multiple organ failure, E5880 therapy in relation to)

IT **128420-61-1**, E5880
RL: BIOL (Biological study)
(platelet-activating factor antagonism by, in sepsis induced disseminated intravascular coagulation and multiple organ failure)

L28 ANSWER 25 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1994:153730 HCAPLUS
DOCUMENT NUMBER: 120:153730
TITLE: Synergistic combinations of PAF antagonists and anticholinergic agents as drugs for treatment of bronchial asthma.
INVENTOR(S): Heuer, Hubert
PATENT ASSIGNEE(S): Boehringer Ingelheim KG, Germany
SOURCE: Ger. Offen., 13 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4219659	A1	19931223	DE 1992-4219659	19920616

PRIORITY APPLN. INFO.: DE 1992-4219659 19920616
OTHER SOURCE(S): MARPAT 120:153730
AB Mixts of hetrazepine deriv. PAF antagonists (Markush given) with anticholinergics are synergistic drugs for treatment of bronchial asthma. The effectiveness of a combination of atropine with WEB 2170 was shown on PAF-induced bronchoconstriction, in guinea pigs.
IT **65154-06-5D**, PAF, antagonists, mixts. with anticholinergics
128420-61-1D, e 5880, mixts. with anticholinergics
RL: BIOL (Biological study)
(drugs for treatment of bronchial asthma, synergistic)

L28 ANSWER 26 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:610708 HCAPLUS
DOCUMENT NUMBER: 119:210708
TITLE: Treatment of dysmenorrhea with PAF antagnoists
INVENTOR(S): Kutter, Eberhard
PATENT ASSIGNEE(S): Boehringer Ingelheim KG, Germany
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4200610	A1	19930715	DE 1992-4200610	19920113
WO 9313776	A1	19930722	WO 1993-EP47	19930112

W: JP, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: DE 1992-4200610 19920113
OTHER SOURCE(S): MARPAT 119:210708
AB PAF antagonists are drugs for the treatment of dysmenorrhea, esp. primary

dysmenorrhea (no data). Suitable PAF antagonists are alprazolam, dilthiazem, brotizolam, hetrazepine derivs., etc. Formulation examples are given. The PAF antagonist 2-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]ethane-1-carboxylic acid morpholide was prepd. by the reaction of 2-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,4]diazepin-2-yl]ethane-1-carboxylic acid with N-hydroxybenzotriazole and morpholine, in abs. DMF.

IT **128420-61-1**, E-5880
RL: BIOL (Biological study)
(PAF antagonist, dysmenorrhea treatment by)

IT **65154-06-5**, Blood platelet-activating factor
RL: BIOL (Biological study)
(antagonist of, as drugs for treatment of dysmenorrhea)

L28 ANSWER 27 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:449384 HCAPLUS
DOCUMENT NUMBER: 119:49384
TITLE: Preparation of 7-(indol-3-yl carbonyl)pyrrolo[1,2-c]thiazoles and related compounds as platelet activating factor antagonists
INVENTOR(S): Summers, James B.; Davidsen, Steven K.; Holms, James H.; Pireh, Daisy; Heyman, H. Robin; Martin, Michael B.; Steinman, Douglas H.; Sheppard, George S.; Carrera, George M., Jr.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9301813	A1	19930204	WO 1992-US5890	19920714
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2112562	AA	19930204	CA 1992-2112562	19920714
AU 9223391	A1	19930223	AU 1992-23391	19920714
AU 651243	B2	19940714		
EP 595924	A1	19940511	EP 1992-915895	19920714
EP 595924	B1	19990414		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
AT 178796	E	19990415	AT 1992-915895	19920714
ES 2131530	T3	19990801	ES 1992-915895	19920714
JP 3135917	B2	20010219	JP 1993-502913	19920714
US 5459152	A	19951017	US 1993-162034	19931202

PRIORITY APPLN. INFO.: US 1991-731681 A2 19910717
WO 1992-US5890 A 19920714

OTHER SOURCE(S): MARPAT 119:49384
GI



I



II

AB Title compds. [I; R1 = H, halo, furyl, thienyl, thiazolyl, pyridyl, pyrimidyl, alkyl, alkoxy, alkanoyl, (substituted) Ph, PhCO, PhO, phenylalkoxy phenylalkanoyl; R2 = H, alkyl, hydroxy(alkyl), carboxy(alkyl), amino(alkyl), acyl(alkyl), sulfonyl(alkyl), sulfamoyl(alkyl), carbamoyl(alkyl); R3-R5 = H, alkyl; X = S, SO, SO2, O, CH2; Y = N, N+R12, N+O-, N+OR12, N+NR7R8, N+NHCOR9, etc.; A = O, NOR10, NOCOR10, NNR7R8; R7-R9 = H, alkyl; R7R8 = heterocyclyl; R10 = H, alkyl, carboxyalkyl, aminoalkyl, hydroxylalkyl, sulfonylalkyl, sulfamoylalkyl, cyanoalkyl, tetrazolylalkyl, CONHNH2, (substituted) phenylalkyl; R12 = alkyl], were prepd. Thus, 3-(pyridin-3-yl)-7-[1-(N,N-dimethyl(carbamoyl)-6-(4-fluorophenyl)indol-3-ylcarbonyl]-1H,3H-pyrrolo[1,2-c]thiazole (prepn. given) was heated with NH2OH.HCl in pyrine/EtOH at 110.degree. to give title compd. II. II inhibited platelet activating factor with Ki = 0.3 nM.

IT **65154-06-5**, Platelet activating factor
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonists, indolylcarbonylpyrrolothiazoles)

IT **147620-29-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as platelet activating factor antagonist)

L28 ANSWER 28 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:252496 HCAPLUS
DOCUMENT NUMBER: 118:252496
TITLE: Blood platelet-activating factor (PAF) levels and effects of PAF antagonist in patients with septic DIC
AUTHOR(S): Tamakuma, Shoetsu; Ono, Satoshi; Shiba, Tadaaki; Isogai, Masahiro; Sekikawa, Takayoshi; Inoue, Shingo; Nakatani, Toshio; Nakano, Akira; Mori, Keiichiro; Tateishi, Akio
CORPORATE SOURCE: Natl. Def. Med. Coll., Tokorozawa, 359, Japan
SOURCE: Igaku no Ayumi (1993), 164(13), 913-4
CODEN: IGAYAY; ISSN: 0039-2359
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB Elevated levels of PAF were found in the blood of 15 patients with septic DIC in comparison to normal controls, as detd. by gas chromatog./mass spectroscopy. Administration of an anti-PAF agent (E 5880) induced a significant increase in the platelet count and improvement of the symptoms due to organ injuries.

IT **128420-61-1**, E 5880
RL: BIOL (Biological study)

(as PAF antagonist, septic disseminated intravascular coagulation response to, in humans)

IT **65154-06-5**, Blood platelet-activating factor
RL: BIOL (Biological study)
(of blood in human with septic disseminated intravascular coagulation)

L28 ANSWER 29 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1992:174669 HCAPLUS
DOCUMENT NUMBER: 116:174669
TITLE: Preparation of sugar analogs as platelet-activating factor (PAF) antagonists
INVENTOR(S): Okano, Kazuo; Asano, Osamu; Shimomura, Naoyuki; Kawahara, Tetsuya; Abe, Shinya; Miyazawa, Shuhei; Miyamoto, Mitsuaki; Yoshimura, Hiroyuki; Harada, Kokichi; Et, Al.
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03200779	A2	19910902	JP 1989-344683	19891227
JP 2933962	B2	19990816		

PRIORITY APPLN. INFO.: JP 1989-344683 19891227
OTHER SOURCE(S): MARPAT 116:174669
GI



I



II



AB Sugar analogs [I; R1-R3 = alkyl; R4 = acyl; A = 3,4,5-trimethoxybenzyloxy, 4-biphenylylmethoxy, etc.; G = 2-pyridyl its quaternary salts; m, n = 1-3], useful as blood platelet aggregation inhibitors, are prepd. Deprotection of 390 mg ether II (R = tetrahydropyran-2-yl) with pyridine p-tosylate in EtOH gave 289 mg alc. II (R = H), which (280 mg) was stirred with pyridine 162, ClCO2Ph 165, and 2-(aminomethyl)pyridine 570 mg in CH2Cl2 at 0.degree. to give 289 mg carbamate II (R = Q, R5 = H) (III). Acetylation of 280 mg III with Ac2O in pyridine gave 218 mg amide deriv.

II (R = Q, R5 = Ac), which (70 mg) was refluxed with EtI to give 60 mg pyridinium salt II.EtI (R = Q, R5 = Ac) (IV). IV showed IC50 of 0.084 .mu.M against PAF-induced platelet aggregation and IC50 of 0.027 .mu.M in PAF receptor binding assay.

IT **65154-06-5**, Platelet-activating factor
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonists, sugar analogs)

IT **138085-48-0P 138085-49-1P 138105-87-0P**
138105-88-1P 138105-89-2P 138105-90-5P
138874-18-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of platelet aggregation inhibitor)

IT **138085-58-2P 138085-60-6P 138085-61-7P**
138085-62-8P 138085-63-9P 138085-64-0P
138085-65-1P 138085-66-2P 138085-67-3P
138085-68-4P 138085-69-5P 138874-19-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as platelet-activating factor antagonist)

L28 ANSWER 30 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1992:41979 HCAPLUS
DOCUMENT NUMBER: 116:41979
TITLE: Preparation of 1-deoxy-or 1,2-dideoxyglucopyranose derivatives as platelet activating factor (PAF) inhibitors
INVENTOR(S): Okano, Kazuo; Asano, Osamu; Shimomura, Naoyuki; Kawahara, Tetsuya; Abe, Shinya; Miyazawa, Shuhei; Miyamoto, Mitsuaki; Yoshimura, Hiroyuki; Harada, Kokichi; Et, Al.
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03200780	A2	19910902	JP 1989-344684	19891227
JP 2933963	B2	19990816		

PRIORITY APPLN. INFO.: JP 1989-344684 19891227
OTHER SOURCE(S): MARPAT 116:41979
GI





AB The title compds. [I; R1 = H, alkoxy; R2 = alkoxy; R3 = O2CNHR5, O2CNR7(CH2)nG, Q; G = 2-pyridyl, Q1; R4 = CH2O2CNR9(CH2)mG1; R5 = alkyl; R6 = H, alkoxy, Ph; R7, R9 = acyl; R8 = H, alkyl; X- = pharmacol. acceptable anion; n, m = 1-3; G1 = 2-pyridyl, Q1, Q2, CH2O2CNHR12; R11 = H, alkoxy, Ph; R12 = alkyl; excluding R3 = O2CNR7(CH2)nG and R4 = CH2O2CNR9(CH2)mG1], useful for treatment and prevention of PAF-assocd. diseases, e.g. inflammation, disseminated intravascular coagulation (DIC), endotoxin shock, asthma, peptic ulcer, and nephritis, are prepd. Thus, acylation of II (R13 = H, R14 = CH2C6H4OMe-4) (prepn. given) with C18H37NCO in refluxing PhMe contg. pyridine, and oxidative deprotection of the resulting II (R13 = CONHC18H37, R14 = CH2C6H4OMe-4) with (NH4)2Ce(NO3)6 in aq. MeCN to give II (R13 = CONHC18H37, R14 = H) followed by condensation with PhO2CCl and 2-aminomethylpyridine in CH2Cl2 contg. pyridine gave II [R13 = CONHC18H37, R14 = N-(2-pyridylmethyl)carbamoyl] which was acetylated with Ac2O in pyridine at 110.degree. for 16 h and then quaternized with EtI under reflux to give II (R13 = CONHC18H37, R14 = CONAcCH2Q1, R8 = Et, X- = I-) (III). III in vitro inhibited PAF-induced coagulation of human blood platelet with IC50 of 0.17 .mu.M.

IT **65154-06-5**, Platelet activating factor
RL: USES (Uses)
(inhibitors, (di)deoxyglucose derivs.)

IT **138198-50-2P 138198-62-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for platelet activating factor inhibitor)

IT **138198-27-3P 138198-28-4P 138198-29-5P**
138198-30-8P 138198-31-9P 138198-32-0P
138198-33-1P 138198-34-2P 138198-37-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as platelet activating factor inhibitor)

L28 ANSWER 31 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1992:6190 HCAPLUS
DOCUMENT NUMBER: 116:6190
TITLE: Preparation of cyclohexanediol derivatives as platelet-activating factor (PAF) antagonists
INVENTOR(S): Okano, Kazuo; Asano, Osamu; Shimomura, Naoyuki; Kawahara, Tetsuya; Abe, Shinya; Miyazawa, Shuhei; Miyamoto, Mitsuaki; Yoshimura, Hiroyuki; Harada, Kokichi; Et, Al.
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03200757	A2	19910902	JP 1989-344682	19891227
JP 2857191	B2	19990210		

PRIORITY APPLN. INFO.: JP 1989-344682 19891227
OTHER SOURCE(S): MARPAT 116:6190
GI



AB The title compds. [I; A = Q (wherein R2, R3, R4 = alkoxy, cycloalkylalkoxy, arylalkoxy), arylmethyl, alkylcarbamoyl, etc.; R1 = acyl; G = 2-pyridyl, dialkylamino; n = 0-3] are prepd. NaH (60%) was added to a soln. of 1,4-cyclohexanediol in DMF with stirring at 80.degree., followed by a soln. of II in DMF with stirring at 50.degree. and 70.degree. to give 37% monoether III, which was dissolved in pyridine and CH2Cl2 and treated with ClCO2Ph under cooling, the ext. was distd. and the residue heated with 2-(aminomethyl)pyridine at 60.degree. to give 94% carbamate IV (R1 = H) (V). KH (35%) was added to a soln. of V in THF with stirring at room temp., followed by 2-MeOC6H4COCl under cooling to give 30% IV (R1 = 2-MeOC6H4CO). Also prepd. were 34 addnl. I which showed IC50 of 0.07-0.155 .mu.M against PAF-induced human blood platelet aggregation.

IT **65154-06-5**, Platelet-activating factor
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonists, cyclohexanediol derivs.)

IT **137780-07-5P 137780-08-6P 137780-11-1P**
137780-14-4P 137780-15-5P 137780-16-6P
137780-17-7P 137780-18-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as platelet-activating factor antagonist)

L28 ANSWER 32 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1991:680530 HCAPLUS
DOCUMENT NUMBER: 115:280530
TITLE: Unexpected internal **peptide**

butoxycarbonylation of a linear N-Me amide **peptide** derived from virginiamycin S and resulting failure for a carboxy-terminal sequencing. Preparation of the tetrapeptide synthon Thr-D-Abu-Pro-MePhe-OBzl

AUTHOR(S): Moerman, Marc C.; Anteunis, Marc J. O.
CORPORATE SOURCE: Lab. Org. Chem., State Univ. Gent, Ghent, B-9000, Belg.

SOURCE: Bulletin des Societes Chimiques Belges (1991), 100(9), 653-63
CODEN: BSCBAG; ISSN: 0037-9646
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 115:280530

GI



I

AB Treatment of linear chain-shortened virginiamycin S1 deriv. I (Abu = 2-aminobutanoic acid, R = H) with di-tert-Bu dicarbonate [(Boc)2O] did not give the expected I (R = Boc) but rather underwent selective tert-butoxycarbonylation at the threonine nitrogen. This reaction is exploited in the conversion of virginiamycin S1 to tetrapeptide ester H-Thr-D-Abu-Pro-MePhe-OCH2Ph in 5 steps and 75% overall yield.

IT **137407-76-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(attempted prepn. of, by dimethylation of linear chain-shortened deriv. via butoxycarbonylation)

IT **137407-79-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and base-induced fragmentation of)

IT **137407-77-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

IT **23152-29-6**, Virginiamycin S1
RL: RCT (Reactant); RACT (Reactant or reagent)
(ring cleavage of, with trifluoroacetic acid)

L28 ANSWER 33 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1991:492829 HCAPLUS
DOCUMENT NUMBER: 115:92829
TITLE: Preparation of glycerin derivatives as platelet-activating factor (PAF) inhibitors
INVENTOR(S): Okano, Kazuo; Asano, Osamu; Shimomura, Naoyuki; Kawahara, Tetsuya; Abe, Shinya; Miyazawa, Shuhei; Miyamoto, Mitsuaki; Yoshimura, Hiroyuki; Harada, Kokichi; Et, Al.
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 32 pp.

CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03038561	A2	19910219	JP 1989-171363	19890703
JP 2843059	B2	19990106		

PRIORITY APPLN. INFO.: JP 1989-171363 19890703
OTHER SOURCE(S): MARPAT 115:92829
GI



I II



III

AB Glycerins [I; A = (substituted) aryl, aralkyl, cyclohexyl, cyclohexylakyl, etc.; B = alkyl, aralkyl; D = Y(CH2)qG wherein Y = OCONR4 (R4 = acyl, carbamoyl), O(CH2)rNR7 (R7 = acyl, r = 1-3), G = 2-pyridyl, dialkylamino, q = 0-3] are prepd. Glycerin deriv. II (2.1 g) (prepn. given) was dissolved in pyridine and treated with 1.2 g ClCO2Ph and then 2.1 g 2-(aminomethyl)pyridine to give 1.7 g carbamate deriv. III (R = H), which was treated with Ac2O in pyridine to give 1.1 g amide deriv. III (R = Ac) (IV). Quaternization of 1.1 g IV with EtI gave 1.0 g salt IV.EtI, which showed IC50 of 0.38 .mu.M against PAF-induced blood platelet aggregation and recovered the PAF-induced blood pressure lowering by 67.8% at 1.0 mg/kg i.v. in rats.

IT **65154-06-5**, Platelet activating factor
RL: USES (Uses)
(inhibitors, glycerin derivs.)

IT **128400-79-3P 128420-66-6P 135423-96-0P 135471-62-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of platelet-activating factor inhibitor)

IT **128400-58-8P 128400-59-9P 128400-60-2P 128400-61-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as platelet-activating factor inhibitor)

L28 ANSWER 34 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1990:459773 HCAPLUS
DOCUMENT NUMBER: 113:59773
TITLE: Preparation of glycerin derivatives as platelet activating factor (PAF) antagonists
INVENTOR(S): Okano, Kazuo; Asano, Osamu; Shimomura, Naoyuki; Kawahara, Tetsuya; Abe, Shinya; Miyazawa, Shuhei; Miyamoto, Mitsuaki; Yoshimura, Hiroyuki; Harada, Koukichi; et al.
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 150 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 353474	A2	19900207	EP 1989-112204	19890704
EP 353474	A3	19910327		
EP 353474	B1	19950405		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FI 8903099	A	19900105	FI 1989-3099	19890626
FI 97883	B	19961129		
FI 97883	C	19970310		
AU 8937213	A1	19900104	AU 1989-37213	19890629
AU 621634	B2	19920319		
US 5037827	A	19910806	US 1989-373350	19890629
CA 1334753	A1	19950314	CA 1989-604528	19890630
DK 8903291	A	19900105	DK 1989-3291	19890703
NO 8902743	A	19900105	NO 1989-2743	19890703
NO 177495	B	19950619		
NO 177495	C	19950927		
CN 1039414	A	19900207	CN 1989-106554	19890703
CN 1041920	B	19990203		
JP 02131467	A2	19900521	JP 1989-171362	19890703
JP 2766319	B2	19980618		
HU 52478	A2	19900728	HU 1989-3355	19890703
HU 208119	B	19930830		
DD 297814	A5	19920123	DD 1989-330340	19890703
HU 62855	A2	19930628	HU 1992-2211	19890703
RU 2040521	C1	19950725	RU 1989-4614654	19890703
AT 120734	E	19950415	AT 1989-112204	19890704
ES 2070148	T3	19950601	ES 1989-112204	19890704
US 5273985	A	19931228	US 1991-710089	19910604
US 5476863	A	19951219	US 1993-129301	19930930
US 5476864	A	19951219	US 1993-129302	19931110
JP 08231508	A2	19960910	JP 1996-30394	19960219
JP 2758584	B2	19980528		

PRIORITY APPLN. INFO.: JP 1988-166386 19880704
US 1989-373350 19890629
US 1991-710089 19910604

OTHER SOURCE(S): MARPAT 113:59773
GI



AB The title compds. [I; A = NH(CH2)mPh, NH(CH2)pC6H4SO2NH2, NH(CH2)3NHCONH2, NH(CH2)4CONH2, etc. (un)substituted at Ph or NH2 group; m, p = 0-6; B = alkyl, aralkyl; R1 = acyl; n = 0-3; G = 2-pyridyl, 2-pyridiniumyl] and A1OCH2CH(OB1)CH2D [A1 = (CH2)nR2; R2 = cyclohexyl, 4-biphenyl, (un)substituted Ph; B = alkyl, arylalkyl; D = Y(CH2)qG; Y = (un)substituted O2CNH or O(CH2)rN, Q, Q1 Q2; q,r = 0-3; G = 2-pyridyl, trialkylammonio salt] useful for the treatment of diseases caused by PAF, e.g. disseminated intravascular coagulation, anaphylactic or hemoribatic shock, and allergic diseases, are prepd. Thus, acylation of 2-O-methyl-3-O-[[N-(2-pyridyl)methyl]carbamoyl]glycerol with 2-aminofluorene and ClCO2CCl3 on the presence of pyridine gave I (A = 2-fluoroenylamino, B = Me, R1 = H, n = 1, G = 2-pyridyl) which was acylated with 2-MeOC6H4COCl in pyridine to give I (R1 = 2-MeOC6H4CO, A, B, n, G = same as above). Quaternization of the latter with EtI gave, after treatment with Amerlite IRA-410 (Cl-), I (G = Q2, R1, A, B, n = same as above). A total of 49 I were prepd. and 17 I (G = 2-pyridiniumyl) in nitro inhibited 3H-PAF binding to the PAF receptor of human platelets with IC50 of 0.00019-3.5 .mu.M.

IT **65154-06-5**, Platelet activating factor
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonists, glycerin dicarbamates)

IT **128400-91-9P 128401-18-3P 128420-66-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for glycerin dicarbamate platelet activating factor antagonist)

IT **128400-44-2P 128400-45-3P 128400-46-4P**
128400-47-5P 128400-48-6P 128400-49-7P
128400-50-0P 128400-51-1P 128400-52-2P
128400-53-3P 128400-54-4P 128400-55-5P
128400-58-8P 128400-59-9P 128400-60-2P
128400-61-3P 128400-66-8P 128400-67-9P
128400-68-0P 128400-69-1P 128400-70-4P
128400-71-5P 128400-72-6P 128400-73-7P
128400-74-8P 128400-75-9P 128400-78-2P
128400-79-3P 128400-80-6P 128400-84-0P
128420-59-7P 128420-60-0P 128420-61-1P
128420-62-2P 128420-63-3P 128420-64-4P
128420-65-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as platelet activating factor antagonist)

L28 ANSWER 35 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1989:595363 HCAPLUS
DOCUMENT NUMBER: 111:195363
TITLE: Orally active aldose reductase inhibitors derived from

bioisosteric substitutions on tolrestat

AUTHOR(S): Wrobel, Jay; Millen, Jane; Sredy, Janet; Dietrich, Arlene; Kelly, Joseph M.; Gorham, Beverly J.; Sestanj, Kazimir

CORPORATE SOURCE: Wyeth-Ayerst Res. Inc., Princeton, NJ, 08543-8000, USA

SOURCE: Journal of Medicinal Chemistry (1989), 32(11), 2493-500
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 111:195363

GI



I

AB A series of aldose reductase inhibitors was prepd. in which structural modifications were made to three positions of the potent, orally active inhibitor tolrestat (I, R = Me, R1 = OMe, X = S) (II), namely, the 6-methoxy substituent, thioamide S, and the N-Me moiety. These compds. were evaluated in two in vitro systems: an isolated enzyme prepn. from bovine lens to assess their intrinsic inhibitory activity and an isolated rat sciatic nerve assay to det. their ability to penetrate membranes of nerve tissue. These compds. were also evaluated in vivo as inhibitors of galactitol accumulation in the lens, sciatic nerve, and diaphragm of galactose-fed rats. Bioisosteric replacement of the 6-methoxy group with a methylthio substituent gave I (R = Me, R1 = SMe, X = S) (III), and replacement of the thioamide substituent with a cyanoamidine gave I (R = Me, R1 = OMe, X = NCN) (IV). Both III and IV retained high in vitro potency but were less potent in vivo than II. Replacement of the N-Me group by a carbomethoxy moiety gave I (R = CO2Me, R1 = OMe, X = S) and led to a substantial redn. in activity in each of the three assays employed. However, this same structural modification of oxotolrestat led to I (R = CO2Me, R1 = OMe, X = O) and resulted in an enhancement of the intrinsic activity and a comparable in vivo potency. The isolated nerve data suggest that some compds. in these series do not readily penetrate into peripheral nerves, and this presumably is a factor in their lack of oral activity.

IT **121731-42-8P 121731-43-9P 121731-44-0P**
121731-45-1P 121731-46-2P 121731-47-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and acidic hydrolysis of, carboxylic acid from)

IT **121731-13-3P 121731-14-4P 121731-15-5P**
121731-16-6P 121731-17-7P 121731-18-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and aldose reductase inhibition by)

IT **121731-29-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and alkylation of, with tert-Bu bromoacetate)

IT **121731-54-2P 121731-55-3P 121731-56-4P**
121731-57-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(prepn. and N-alkylation of, with tert-Bu bromoacetate)

L28 ANSWER 36 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1987:534225 HCAPLUS
DOCUMENT NUMBER: 107:134225
TITLE: 4-Substituted-2-oxabicyclo[2.2.1]heptane ether herbicides
INVENTOR(S): Powell, James E.
PATENT ASSIGNEE(S): Shell Oil Co., USA
SOURCE: U.S., 15 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4606753	A	19860819	US 1984-621011	19840615

PRIORITY APPLN. INFO.: US 1984-621011 19840615
OTHER SOURCE(S): CASREACT 107:134225
GI



I

AB Oxabicycloalkane ethers, including the title compds. I (X = bond, CMe2; Y = bond, CH2, such that both X and Y are not a single bond; R = H, COR3, R3 = H, hydrocarbyl; R1 = hydrocarbyl, ester, H2NCO; R2 = cyano, aryl, heterocyclyl, cycloalkyl, etc.), useful as herbicides or plant growth regulators, were prepd. Thus, 1,3,3-trimethyl-6-endo-(phenylmethoxy)-2-oxabicyclo[2.2.1]heptane-4-carbonyl isocyanate, prepd. in 11 steps from NCCH2CO2Me, in CH2Cl2 was treated with MeNH2 to give 1,3,3-trimethyl-N-(methylaminocarbonyl)-6-endo-(phenylmethoxy)-2-oxabicyclo[2.2.1]heptane-4-carboxamide (II). In postemergence tests II gave 100% control of barnyard grass and downy brome.

IT **105919-10-6P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as herbicide and plant growth regulator)

L28 ANSWER 37 OF 37 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1979:204491 HCAPLUS
DOCUMENT NUMBER: 90:204491
TITLE: Taurine and glycine derivatives
INVENTOR(S): Gallo-Torres, Hugo; Guthrie, Robert William; Hamilton, James Guthrie; Kierstead, Richard Wightman; Sullivan, Ann Clare
PATENT ASSIGNEE(S): Hoffmann-La Roche, Inc., USA
SOURCE: U.S., 12 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4104285	A	19780801	US 1977-790164	19770422

PRIORITY APPLN. INFO.: US 1977-790164 19770422
GI



I

AB Cholanoyl amino acids I (R = H, alkanoyloxy, BzO; R1 = CO2H, alkoxycarbonyl, CH2SO3H; m, n = 0, 1) were prepd. Thus, 9.87 g 3.alpha.,12.alpha.-dihydroxy-24-nor-5.beta.-cholanic acid was treated with ClCO2Et to give the carbonate, which was treated with 1.96 g glycine to give 7.8 g I (R = H, R1 = CO2H, m = n = 1). I inhibits pancreatic lipase in vitro and hypolipemic in rats.

IT **9001-62-1**
RL: PROC (Process)
(inhibition of, by cholanoylglycine and cholanoyltaurine derivs.)

IT **70118-04-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with glycine)

=> select hit rn 128 1-37
E1 THROUGH E163 ASSIGNED

=> fil reg
FILE 'REGISTRY' ENTERED AT 09:44:32 ON 29 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2003 HIGHEST RN 594810-89-6
DICTIONARY FILE UPDATES: 28 SEP 2003 HIGHEST RN 594810-89-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
=>

=> d his l29-

(FILE 'HCAPLUS' ENTERED AT 09:40:26 ON 29 SEP 2003)
SELECT HIT RN L28 1-37

FILE 'REGISTRY' ENTERED AT 09:44:32 ON 29 SEP 2003
L29 163 S E1-E163
L30 135 S L29 AND L18

=> d reg l30 1-13
1 RN **512853-02-0** REGISTRY
2 RN **259825-61-1** REGISTRY
3 RN **259825-54-2** REGISTRY
4 RN **259825-46-2** REGISTRY
5 RN **259825-39-3** REGISTRY
6 RN **259825-33-7** REGISTRY
7 RN **259825-25-7** REGISTRY
8 RN **259825-24-6** REGISTRY
9 RN **259825-12-2** REGISTRY
10 RN **259825-11-1** REGISTRY
11 RN **259825-05-3** REGISTRY
12 RN **259824-82-3** REGISTRY
13 RN **259824-73-2** REGISTRY

=> d reg l30 14-135
14 RN **259824-70-9** REGISTRY
15 RN **255377-83-4** REGISTRY
16 RN **243862-55-7** REGISTRY
17 RN **226087-56-5** REGISTRY
18 RN **219909-76-9** REGISTRY
19 RN **174290-78-9** REGISTRY
20 RN **174147-85-4** REGISTRY
21 RN **174147-84-3** REGISTRY
22 RN **174147-83-2** REGISTRY
23 RN **156720-74-0** REGISTRY
24 RN **156720-45-5** REGISTRY
25 RN **156720-41-1** REGISTRY
26 RN **156720-40-0** REGISTRY
27 RN **156719-93-6** REGISTRY
28 RN **156719-80-1** REGISTRY
DR 186752-14-7
29 RN **156719-78-7** REGISTRY
DR 186752-13-6
30 RN **156719-77-6** REGISTRY
DR 186752-12-5
31 RN **153735-22-9** REGISTRY
32 RN **153735-21-8** REGISTRY
33 RN **153735-20-7** REGISTRY
34 RN **147620-29-9** REGISTRY
35 RN **138874-19-8** REGISTRY
36 RN **138874-18-7** REGISTRY
37 RN **138198-62-6** REGISTRY
38 RN **138198-50-2** REGISTRY
39 RN **138198-37-5** REGISTRY

40	RN	**138198-34-2**	REGISTRY
41	RN	**138198-33-1**	REGISTRY
42	RN	**138198-32-0**	REGISTRY
43	RN	**138198-31-9**	REGISTRY
44	RN	**138198-30-8**	REGISTRY
45	RN	**138198-29-5**	REGISTRY
46	RN	**138198-28-4**	REGISTRY
47	RN	**138198-27-3**	REGISTRY
48	RN	**138105-90-5**	REGISTRY
49	RN	**138105-89-2**	REGISTRY
50	RN	**138105-88-1**	REGISTRY
51	RN	**138105-87-0**	REGISTRY
52	RN	**138085-69-5**	REGISTRY
53	RN	**138085-68-4**	REGISTRY
54	RN	**138085-67-3**	REGISTRY
55	RN	**138085-66-2**	REGISTRY
56	RN	**138085-65-1**	REGISTRY
57	RN	**138085-64-0**	REGISTRY
58	RN	**138085-63-9**	REGISTRY
59	RN	**138085-62-8**	REGISTRY
60	RN	**138085-61-7**	REGISTRY
61	RN	**138085-60-6**	REGISTRY
62	RN	**138085-58-2**	REGISTRY
63	RN	**138085-49-1**	REGISTRY
64	RN	**138085-48-0**	REGISTRY
65	RN	**137780-18-8**	REGISTRY
66	RN	**137780-17-7**	REGISTRY
67	RN	**137780-16-6**	REGISTRY
68	RN	**137780-15-5**	REGISTRY
69	RN	**137780-14-4**	REGISTRY
70	RN	**137780-11-1**	REGISTRY
71	RN	**137780-08-6**	REGISTRY
72	RN	**137780-07-5**	REGISTRY
73	RN	**137407-79-5**	REGISTRY
74	RN	**137407-77-3**	REGISTRY
75	RN	**135471-62-4**	REGISTRY
76	RN	**135423-96-0**	REGISTRY
77	RN	**128420-66-6**	REGISTRY
78	RN	**128420-65-5**	REGISTRY
79	RN	**128420-64-4**	REGISTRY
80	RN	**128420-63-3**	REGISTRY
81	RN	**128420-62-2**	REGISTRY
82	RN	**128420-61-1**	REGISTRY
83	RN	**128420-60-0**	REGISTRY
84	RN	**128420-59-7**	REGISTRY
85	RN	**128401-18-3**	REGISTRY
86	RN	**128400-91-9**	REGISTRY
87	RN	**128400-84-0**	REGISTRY
88	RN	**128400-80-6**	REGISTRY
89	RN	**128400-79-3**	REGISTRY
90	RN	**128400-78-2**	REGISTRY
91	RN	**128400-75-9**	REGISTRY
92	RN	**128400-74-8**	REGISTRY
93	RN	**128400-73-7**	REGISTRY
94	RN	**128400-72-6**	REGISTRY
95	RN	**128400-71-5**	REGISTRY
96	RN	**128400-70-4**	REGISTRY
97	RN	**128400-69-1**	REGISTRY
98	RN	**128400-68-0**	REGISTRY
99	RN	**128400-67-9**	REGISTRY
100	RN	**128400-66-8**	REGISTRY
101	RN	**128400-61-3**	REGISTRY
102	RN	**128400-60-2**	REGISTRY

```
103       RN   128400-59-9  REGISTRY
104       RN   128400-58-8  REGISTRY
105       RN   128400-55-5  REGISTRY
106       RN   128400-54-4  REGISTRY
107       RN   128400-53-3  REGISTRY
108       RN   128400-52-2  REGISTRY
109       RN   128400-51-1  REGISTRY
110       RN   128400-50-0  REGISTRY
111       RN   128400-49-7  REGISTRY
112       RN   128400-48-6  REGISTRY
113       RN   128400-47-5  REGISTRY
114       RN   128400-46-4  REGISTRY
115       RN   128400-45-3  REGISTRY
116       RN   128400-44-2  REGISTRY
117       RN   121731-57-5  REGISTRY
118       RN   121731-56-4  REGISTRY
119       RN   121731-55-3  REGISTRY
120       RN   121731-54-2  REGISTRY
121       RN   121731-47-3  REGISTRY
122       RN   121731-46-2  REGISTRY
123       RN   121731-45-1  REGISTRY
124       RN   121731-44-0  REGISTRY
125       RN   121731-43-9  REGISTRY
126       RN   121731-42-8  REGISTRY
127       RN   121731-29-1  REGISTRY
128       RN   121731-18-8  REGISTRY
129       RN   121731-17-7  REGISTRY
130       RN   121731-16-6  REGISTRY
131       RN   121731-15-5  REGISTRY
132       RN   121731-14-4  REGISTRY
133       RN   121731-13-3  REGISTRY
134       RN   105919-10-6  REGISTRY
135       RN    70118-04-6  REGISTRY


=> d ide can 1 10 20 30 40 50 60 70 80 90 100 110 120 130 135

L30  ANSWER 1 OF 135  REGISTRY  COPYRIGHT 2003 ACS on STN
RN   512853-02-0  REGISTRY
CN   Carbamic acid, [[(6S)-hexahydro-6-[(4-hydroxyphenyl)methyl]-2-methyl-8-(1-
     naphthalenylmethyl)-4,7-dioxo-2H-pyrazino[2,1-c][1,2,4]triazin-1(6H)-
     yl]carbonyl]-, phenylmethyl ester (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C34 H33 N5 O6
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:321579

L30 ANSWER 10 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **259825-11-1** REGISTRY
CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-(4R)-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-L-prolyl-O-[(1,1-dimethylethyl)dimethylsilyl]-4-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-L-threonyl-O-[(1,1-dimethylethyl)dimethylsilyl]-L-threonyl-N,N-bis[(1,1-dimethylethoxy)carbonyl]-3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-methyl-, (3S,4S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C78 H138 N6 O16 Si5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:194661

L30 ANSWER 20 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **174147-85-4** REGISTRY
CN Carbamic acid, (2,4-dimethoxybenzoyl)[2-hydroxy-1-(phenylmethyl)-2-(2-thiazolyl)ethyl]-, 1,1-dimethylethyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C26 H30 N2 O6 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 124:203052

L30 ANSWER 30 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **156719-77-6** REGISTRY
CN threo-Pentitol, 2,3,4-trideoxy-2,4-epithio-, [(1-ethylpyridinium-2-yl)methyl](2-methoxybenzoyl)carbamate octadecylcarbamate, chloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thietane, pyridinium deriv.
FS STEREOSEARCH
DR 186752-12-5
MF C41 H64 N3 O6 S . Cl
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Relative stereochemistry.



● Cl⁻

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 126:157369

REFERENCE 2: 124:202845

REFERENCE 3: 123:314308

REFERENCE 4: 121:133939

L30 ANSWER 40 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **138198-34-2** REGISTRY
CN D-Glucitol, 1,5-anhydro-4-O-([1,1'-biphenyl]-4-ylmethyl)-2,3-di-O-methyl-, [(1-ethylpyridinium-2-yl)methyl](2-methoxybenzoyl)carbamate, iodide (9CI) (CA INDEX NAME)
MF C38 H43 N2 O8 . I
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



● I^-

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 116:41979

L30 ANSWER 50 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **138105-88-1** REGISTRY
CN D-glycero-D-gulo-Heptitol, 2,6-anhydro-3,4,5-tri-O-methyl-, 7-(hexadecylcarbamate) 1-[(2-methoxybenzoyl)(2-pyridinylmethyl)carbamate] (9CI) (CA INDEX NAME)
MF C42 H65 N3 O10
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 116:174669

L30 ANSWER 60 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **138085-61-7** REGISTRY
CN D-glycero-D-gulo-Heptitol, 2,6-anhydro-3,4,5-tri-O-methyl-, 1-[[(1-ethylpyridinium-2-yl)methyl](2-methoxybenzoyl)carbamate] 7-(undecylcarbamate), chloride (9CI) (CA INDEX NAME)
MF C39 H60 N3 O10 . Cl
SR CA
LC STN Files: CA, CAPLUS



● Cl^-

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 116:174669

L30 ANSWER 70 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **137780-11-1** REGISTRY
CN Pyridinium, 1-ethyl-2-[[(2-methoxybenzoyl)[[[4-[(3,4,5-trimethoxyphenyl)methoxy]cyclohexyl]oxy]carbonyl]amino]methyl]-, iodide (9CI) (CA INDEX NAME)
MF C33 H41 N2 O8 . I
SR CA
LC STN Files: CA, CAPLUS



● I^-

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 116:6190

L30 ANSWER 80 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **128420-63-3** REGISTRY
CN Carbamic acid, (2-methoxybenzoyl)(2-pyridinylmethyl)-, 2-methoxy-3-[[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]oxy]propyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H31 N3 O8
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 113:59773

L30 ANSWER 90 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **128400-78-2** REGISTRY
CN Carbamic acid, (2-methoxybenzoyl)(2-pyridinylmethyl)-,

3-[3,5-dimethoxy-4-(octadecyloxy)phenoxy]-2-methoxypropyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C45 H66 N2 O9
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 113:59773

L30 ANSWER 100 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **128400-66-8** REGISTRY
CN Carbamic acid, (2-methoxybenzoyl)(2-pyridinylmethyl)-, 2-methoxy-3-[[[[3-(octadecyloxy)propyl]amino]carbonyl]oxy]propyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C41 H65 N3 O8
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 113:59773

L30 ANSWER 110 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **128400-50-0** REGISTRY
CN Pyridinium, 1-ethyl-2-[6-methoxy-2-(2-methoxybenzoyl)-14-(4-morpholinyl)-3,9,14-trioxo-4,8-dioxa-2,10-diazatetradec-1-yl]-, chloride (9CI) (CA INDEX NAME)

MF C30 H41 N4 O9 . Cl
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



● Cl^-

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 113:59773

L30 ANSWER 120 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **121731-54-2** REGISTRY
CN Carbamic acid, [[6-methoxy-5-(trifluoromethyl)-1-naphthalenyl]carbonyl]-, propyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H16 F3 N O4
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 111:195363

L30 ANSWER 130 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **121731-16-6** REGISTRY
CN Glycine, N-[[6-methoxy-5-(trifluoromethyl)-1-naphthalenyl]carbonyl]-N-[(1-methylethoxy)carbonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD

MF C19 H18 F3 N O6
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 112:56693

REFERENCE 2: 111:195363

L30 ANSWER 135 OF 135 REGISTRY COPYRIGHT 2003 ACS on STN
RN **70118-04-6** REGISTRY
CN Carbamic acid, [[(3.alpha.,5.beta.,12.alpha.,17.beta.)-3,12-dihydroxyandrostan-17-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Androstane, carbamic acid deriv.
MF C23 H37 N O5
LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 90:204491